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GENERAL ABSTRACT 
 
Skin delivery of drugs, which means delivery directly into the epidermis, represents 
today an interesting alternative to hypodermic injection and cutaneous 
administration. The main difficulty in current techniques of skin release, for 
example patches, is linked to the poor permeability of the horny layer of the skin, 
which obstructs the passage of large, charged and hydrophilic molecules.  
Microneedles, inserted into the skin in order to cross the stratum corneum, which is 
the outer layer of the epidermis, can solve the permeability issue without causing 
pain or harm to the patient. Among the many advantages of the use of microneedles 
as compared to the conventional methods: it‘s possible introduce high molecular 
weight; it can be mentioned reducing the patient's pain during administration of the   
active principles compared to hypodermal injections and the possibility of self-
administration of the drug by the patient without the need of the intervention of 
specialized personnel. Furthermore, when integrated into suitable miniaturized 
systems, the use of microneedles can allow a controlled release of small amounts of 
molecules, at the predetermined site, in a correct countable concentration and in a 
determinate time. 
Microneedles are well known in the pharmaceutical and cosmeceutical field as 
effective and pain-free micro-scale devices employed for skin release, transdermal 
vaccination and drug delivery. Preliminary results show that microneedles 
represent a promising technology to deliver therapeutic compounds into the skin 
for a range of possible applications, in fact microneedles have been studied in vitro, 
in vivo for a variety of applications. Many researchers have produced microneedles 
with different designs and different materials by means of various fabrication 
processes. However, the majority of the known techniques are not suitable for 
sensitive drugs and active molecules, in particular those thermo-labile, since they 
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often involve high temperatures, while the processes carried out at room 
temperature usually involve hazardous photoinitiators. 
The aim of this work is a new stamp based method to fabricate multi-
compartmental polymeric microneedles containing a model drug. This approach 
overcomes the limitations deriving from the known methods for the production of 
polymer microneedles, e.g. micro-casting and drawing lithography; since no 
hazardous temperatures; no multi-step filling process and no UV are required. 
The process is divided in two parts to obtain microneedles with two types of 
possible release. Two different processes were used to produce microneedles. 
In the first process microparticles were placed in the cavities of the elastomeric 
PDMS mold obtained from the previously produced master and subsequently 
softened by means of a suitable vapor mixture in order to produce the 
microneedles, then a polymeric solution of PVP was cast on the mold. In the 
second process, a polymeric solution of PVP was cast on the mold to create a tip 
array, then microspheres were placed in the cavities and subsequently softened by 
means of a suitable vapor mixture in order to produce the microneedles body. 
Later, the microneedles were collected from the mold with the aid of a PVP 
covered medical tape and to remove the microneedles array from the mold.  
The microneedles‘ porous structure allows to modulate the degradation of the 
polymer and provides a better control of the release profile of the embedded drug. 
This method allows to preserve both the microstructure and molecule distribution 
of the starting microspheres, providing shaped microparticles that can be released 
over time. In particular, in this work it is demonstrated that the shaped 
microparticles keep a porous microstructure and cargo distribution similar to that of 
the starting microspheres, whereby the release of enzyme embedded in the shaped 
microparticles and starting microspheres is equivalent. 
The microneedles porous structure allows modulating the degradation of the 
polymer and a better control of the profile release of the drug contained in it. This 
process overcomes several limitations of the known methods for the production of 
12 
 
polymer microneedles and has very promising applications in the pharmaceutical 
and cosmetceutical industry. 
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CHAPTER I 
 
STATE OF ART 
 
1. Introduction 
The ultimate aim of every therapy is to restore the normalcy of life, but ironically 
sometimes, the requirements of treatment are such that the normal rhythm of life is 
disturbed. Most drugs are administered in the form of pills or injections, but these 
methods of delivery are not always optimal.[1, 2] Medication taken orally must not 
only be absorbed successfully out of the intestine into the bloodstream, but must 
also survive the harsh and enzyme-rich environments of the gastrointestinal tract or 
the first pass through the liver. Drugs that cannot be taken as pills are typically 
administered by injection, which introduces the problems of pain, infection, and 
expertise required to carry out an injection. Both the methods of delivery have 
limitations, as the full dose of drug is introduced into the body at one time. An 
approach which is more appealing to patients and offers the possibility of 
controlled release over time is transdermal drug delivery. Clinical benefits, industry 
interest and regulatory precedence had predicted a strong market for transdermal 
drug products due to the limitations of conventional drug deliveries. However, 
transdermal delivery is severely limited by the inability of the large majority of 
drugs to cross skin at therapeutic rates due to the barrier imposed by the stratum 
corneum, the outer 10/15 µm of skin, that generally allows the transport only of 
small molecules (<400 Da).[3] In order to address this limitation, a variety of 
methods to increase transdermal transport have been studied, including chemical 
enhancers, electric fielders, ultrasound, and thermal methods.[4-6] Although still 
under active investigation, these enhancement methods have made only limited 
impact on medical practice to date. Recently several research groups have focused 
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the attention on overcoming problems associated with the barrier properties of the 
skin, reducing skin irritation rates and improving the aesthetics associated with 
passive patch systems. A new approach to transdermal drug delivery that acts as a 
bridge between the user-friendliness of patches and the broad effectiveness of 
hypodermic needles has recently received attention.[4, 5, 7] By using needles of 
micrometer dimensions, termed microneedles, skin can be pierced to effectively 
deliver drugs, but with a minimally invasive and painless manner that lends itself to 
self-administration and slow delivery over time. It is proposed that micron-scale 
holes in the skin are likely to be safe, given that they are smaller than holes made 
by hypodermic needles or minor skin abrasions encountered in daily life.[1] 
1.1 Control of drug delivery 
The control of drug concentration in the blood or in a specific area of the body is 
very important, for this reason there are already numerous pharmaceutical forms 
that allow for a delayed release, or by which the speed and duration of release of 
the active ingredient can be ―programmed‖. Such formulations are defined 
―controlled release systems‖ and allow for the setting of the blood level of the drug, 
so as to avoid phenomena of sub-or over dosage and minimize unwanted side 
effects. Conventional methods of administration of drugs normally do not allow to 
obtain a controlled release over time of active ingredient: in many cases, there is a 
sudden release of the drug from the pharmaceutical form and this can lead in a 
short time to reach the limit of toxicity, namely the concentration at which the 
active principle involves side effects or toxicity. 
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Fig. 1.1. Comparison between a conventional delivery system and a system of controlled release.[8]  
 
Once given the drug, it keeps to a relatively short therapeutic limit and 
subsequently its blood levels decrease slowly until the next administration. 
Therefore, the desired therapeutic effects may be obtained only by repeated 
administration of the drug, which are often not well accepted by the patient in 
addition to being very expensive. 
The modern pharmaceutical technology has successfully attempted to overcome 
these problems with the creation of systems for controlled release of drugs, namely 
of pharmaceutical preparations which, once administered to the patient, are capable 
to release over time the active principle contained in them, ensuring its constant 
concentration in the blood. In this way the frequency of administration can be 
reduced with advantages both for the patient and the cost of therapy. 
The result of the research carried out in this area is also represented by the 
innovative use of particular polymers as a means of releasing and targeting 
biologically active molecules. These polymers are able to allow an increase in the 
residence time of the drug in the bloodstream, reduce antigenicity, and increase 
stability against enzymes and a greater bioavailability. 
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In order to achieve a gradual or prolonged release of the active ingredient, various 
pharmaceutical formulations have been developed which can be divided into three 
groups:  
- sustained release: the medicine administered dissolves quickly providing an 
initial dose of active ingredient within the therapeutic range and is able to 
release for a certain time a lower dose. In fact, the concentration is not 
maintained constant but fluctuates within the therapeutic band;  
- long-acting: the amount of drug administered is slightly greater than that 
required to reach the desired therapeutic response. In this way, without 
producing hazardous pudding, a prolonged effect is achieved, as compared 
to the normal dose since the body uses more time to eliminate or metabolize 
the drug;  
- repeat-action: provides an initial dose of medicine which is released later 
when the effect of the first is fading.  
For the production of medicines of this type various techniques can be employed, 
which are distinguished on the basis of the method by which the active principle is 
locked inside the pharmaceutical preparation.  
This can happen by means of:  
- physical locking by external coatings and excipients (currently the most 
common method);  
- entrapment by ion-exchange resins; 
- encapsulation using biodegradable polymers.  
According to a relatively new technique, the drug is embedded in a biodegradable 
polymer matrix, and the active substance is released through diffusion, degradation 
and/or erosion processes of the matrix itself.  
The controlled release systems that use polymeric substances are classified 
according to the mechanism that controls the release of the drug.  
Pharmaceutical forms aiming to control the diffusional mechanisms by which the 
release speed is determined are the most used in the pharmaceutical industry and 
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can be divided into systems and reservoir matrix systems. For what concerns the 
systems, the drug is present as a core coated by a diffusional barrier of the 
polymeric type and this involves a release rate that follows a zero-order kinetics, at 
least for a certain time. Fig. 1.2 shows a typical profile of the rate of release of this 
system.  
In matrix systems the active substance is dissolved or dispersed in an inert polymer 
matrix. A different approach involves the use of an erodible polymer, namely 
control chemical, in which the drug is ideally distributed evenly over the entire 
polymer matrix and its release is generally governed by a combined effect of 
polymer degradation and diffusion. In this way a kinetic release of the first order is 
usually achieved, even though more complicated kinetics has also been observed, 
since the diffusion of the drug is affected by the degradation of the matrix (fig. 1.2). 
 
 
Fig. 1.2. Kinetics of drug release.[9] 
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1.1.1 Materials for controlled release 
There are numerous techniques that allow to obtain gradual drug release using 
polymers. The easiest method to realize monolithic systems with predetermined 
geometric shape and dimensions, consists in creating an environment adequately 
concentrating organic solutions of polymers containing the drug of interest, and 
then proceed with the slow evaporation of the solvent. With this method, polymers 
that are soluble in organic solvents must be used. The evaporation must take place 
under well controlled conditions to avoid the formation of sediment, bubbles, or 
clusters. Other methods for preparing polymer matrices involve the use of UV. All 
these techniques have the drawback of providing a final product which is polluted 
by unwanted residual substances, in some cases even toxic, so it is necessary to 
perform downstream operations of separation and purification, such as filtration 
and washing, thus affecting the final cost of the preparation and creating products 
which are difficult to dispose. 
The choice of the polymer used to realize the device has to be made carefully.  
An ideal material should be inert and without impurities, biocompatible and easily 
to process. The type of material also depends on the kind of issues that one would 
like to accomplish and the type of drug incorporated.  
After the work,[10] hydrogels have gained an increasing interest for their 
hydrophilic character and their biocompatibility, so that recently some hydrogels 
have become particularly suitable for tissue engineering. 
Hydrogels are hydrophilic polymers characterized by a network capable of 
absorbing water up to one hundred times their dry weight, and can be chemically 
stable or can degrade and eventually dissolve. Gels are called ―reversible‖ or 
―physical‖ when the network is held together by secondary forces, such as ionic 
forces or hydrogen bridges. On the other hand, gels are called ―permanent‖ or 
―chemical‖ when covalently cross-linked.   
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Fig. 1.3 shows the formula of the chemical hydrogel Poly (2-hydroxyethyl-
methacrylate) (PHEMA). 
 
 
Fig. 1.3. Structural formula of poly (2-hydroxyethyl-methacrylate), PHEMA. 
 
Due to its high biocompatibility, PHEMA has found wide use in the biomedical 
field, especially in those areas where a good interaction with biological fluids is 
needed, such as contact lenses. PHEMA is a type of hydrogel that commonly has a 
three-dimensional network and is able to consider a large amount of water without 
dissolving.  
For this class of materials, the kinetics of water absorption is very relevant: the 
drug, immobilized in the dry hydrogel, is released when the water absorbed swells 
the polymer matrix. For this reason, a controlled swelling of the hydrogel implies a 
controlled release of the drug. 
In recent years, other alternative material usable for forming microneedles were 
used. Carboxymethyl-cellulose (CMC) (fig. 1.4), is an organic polymer obtained by 
reacting cellulose with caustic soda (NaOH) and monochloroacetic acid (MCAA) 
(ClCH2COOH) (fig. 1.5).[3]  
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Fig. 1.4. Structural formula of CMC. 
 
 
Fig. 1.5. Exemplified reaction scheme of carboxymethylcellulose. 
 
It is a kind of material already used in many different areas due to its ability to 
stabilize the solutions. It can also be used in the biomedical field since it is 
biocompatible, readily biodegradable in water and approved by FDA. Moreover, it 
is expected to be mechanically strong due to its relatively high Young‘s modulus  
(1 GPa).[11]  
Another material that is arising interest in the development of biodegradable 
devices is poly (hydroxybutyrate) – PHB (fig. 1.6), biodegradable thermoplastic 
polyester produced by bacterial fermentation, whose biodegradation time is short. 
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Fig. 1.6. Structural formula of polyhydroxy butyrate (PHB). 
 
PHB is a polymer with high crystallinity (50-70%) and an elasticity modulus of 
3GPa; however PHB has some disadvantages, such as high fragility, showing 3-5% 
tensile elongation at break, and low thermal stability above its melting point.[11]  
An alternative to improve these properties and PHB processability is to mix it with 
another polymer. Very recently, Scandola et al. have disclosed that 
polyhyroxybutyrate (PHB) forms miscible blends with cellulose esters,[12] as 
cellulose acetate propionates (CAP) and cellulose acetate butyrate (CAB).  
From a study by Buchanan, that used a copolymer poly(hydroxybutyrate-co-
valerate) (PHBV) (fig. 1.7).  
 
 
Fig. 1.7. Structural formula of polyhydroxy butyrate-co-valerate (PHBV). 
It is clear that mixing PHBV and CAB, in the range 20-50% PHBV, can improve 
elongation at break, while the tear strength is largely unaffected, as shown in fig. 
1.8.[13] 
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Fig. 1.8. Change in tear strength and elongation at break of the CAB/PHBV blends 
containing 0-100% PHBV[12]. 
 
However, polymers of lactic acid and glycolic acid and their copolymers, such as 
lactic-co-glycolic acid, are so far the most interesting and widely used in the release 
of drugs and in the development of biomaterials. These polymers were originally 
used as materials for absorbable sutures, and thereafter have been used for 
manufacturing biodegradable release systems. Polylactides are polyesters that have 
the advantage to decompose into fragments, biologically acceptable by the host, 
which are then metabolized and removed through normal metabolic processes. 
These polymers are, in fact, essentially non-toxic and biodegradable (fig.1.9). 
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Fig. 1.9. Structural formula of PLA, PGA and their copolymer PLGA. 
The mechanism of degradation for all polyesters seems to be a simple 
homogeneous autocatalytic reaction. The rate of erosion depends on the chemical 
structure, the morphology of the polymer matrix and the crystallinity. 
1.2 Transdermal drug delivery 
Transdermal drug delivery systems are topically administered medicaments in the 
form of patches that deliver drugs for systemic effects at a predetermined and 
controlled rate. Often, this promotes healing to an injured area of the body. An 
advantage of a transdermal drug delivery route over other types such as oral and 
topical, is that it provides a controlled release of the medicament into the patient. 
Drug is meanly delivered through the skin with the aid of transdermal patch. A 
transdermal patch is a medicament adhesive patch that is placed on the skin to 
deliver a specific dose of medication through the skin into the bloodstream over 
time. However, a disadvantage related to the development of transdermal patches, 
stems from the fact that the skin is a very effective barrier. The transdermal route is 
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indeed desirable, but there is one small obstacle: the skin‘s function is to keep 
things out of the body.  
1.2.1 Skin structure 
In order to design effective transdermal drug delivery systems, it is necessary to 
have a proper knowledge of the skin structure. Indeed, if the barrier provided by the 
stratum corneum is not crossed, active molecules cannot be properly delivered.  
The integument or skin is the largest organ of the body, making up 16% of 
bodyweight, with a surface area of 1.8 m
2
. It has several functions, the most 
important being to form a physical barrier to the environment, allowing and 
limiting the inward and outward passage of water, electrolytes and various 
substances while providing protection against micro-organisms, ultraviolet 
radiation, toxic agents and mechanical injures. There are three structural layers of 
the skin: the epidermis, the dermis and subcutis (fig.1.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10. Structure of the skin. 
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The epidermis is the outer layer, serving as the physical and chemical barrier 
between the interior body and exterior environment; the dermis is the deepest layer 
providing the structural support of the skin, below which is a loose connective 
tissue layer, the subcutis or hypodermis which is an important depot of fat. 
The epidermis is a stratified squamous epithelium.[14] The main cells of the 
epidermis are the keratinocytes, which synthesizes the protein keratin 
epithelium.[14] Protein bridges called desmosomes connect the keratinocytes, 
which are in a constant state of transition from the deeper layers to the superficial 
one. The four separate layers of the epidermis are formed by the differing stages of 
keratin maturation. The epidermis varies in thickness from 0.05 mm on the eyelids 
to 0.8±1.5 mm on the soles of the feet and palms of the hand. Moving from the 
lowest layers upwards to the surface, the four layers of the epidermis are:   stratum 
basal (basal or germinativum cell layer) 
 stratum spinosum (spinous or prickle cell layer) 
 stratum granulosum (granular cell layer) 
 stratum corneum (horny layer). 
The final outcome of keratinocyte maturation is found in the stratum corneum, 
which is made up of layers of hexagonal-shaped, non-viable cornified cells known 
as corneocytes. In most areas of the skin, there are 10±30 layers of stacked 
corneocytes with the palms and soles having the most. Each corneocyte is 
surrounded by a protein envelope and is filled with water-retaining keratin proteins. 
The cellular shape and orientation of the keratin proteins add strength to the 
stratum corneum. The cells are surrounded in the extracellular space by stacked 
layers of lipid bilayers (fig 1.11).  
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Fig 1.11. Structure of the epidermis. 
 
The resulting structure provides the natural physical and water-retaining barrier of 
the skin. The corneocyte layer can absorb three times its weight of water but if its 
water content drops below 10% it no longer remains pliable and cracks. The 
movement of epidermal cells to this layer usually takes about 28 days and is known 
as the epidermal transit time. 
The dermis is a complex structure composed of two layers: thin papillary layer, and 
the thicker reticular layer. The structure is highly irregular, whit dermal papillae 
from the papillary dermis projecting perpendicular to the skin surface. It is via 
diffusion at this junction that the epidermis obtains nutrients and disposes waste. 
The dermo-epidermal junction flattens during ageing which accounts in part for 
some of the visual signs of ageing. The subcutis is composed by loose connective 
tissue and fat, which can be up to 3 cm thick on the abdomen. 
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1.2.2 Devices and technologies for transdermal delivery 
From a global perspective, advances in transdermal delivery systems can be 
categorized in three different generations. The first generation is mainly based on 
today‘s patches produced by judicious selection of drugs that can cross the skin at 
therapeutic rates with little or no enhancement. In addition to patches, in this class 
are included liquid spray, gel and other topical formulation. The second generation 
is characterized by additional advances for the delivery of small-molecules by 
means of an increase of skin permeability and the use of driving forces for 
transdermal transport; an example is provided by chemical enhancers conjugated to 
the drug. The third generation is meant to enable transdermal delivery of small-
molecule drugs, macromolecules (including proteins and DNA) and virus based 
and other vaccines through targeted permeabilization of the skin‘s stratum 
corneum.[15] 
The kind of technology used by transdermal devices can be divided into passive or 
active methods based on whether or not an external source of energy is used for 
skin permeation enhancement. Passive methods include use of chemical enhancers, 
emulsions and lipid assemblies that increase stratum corneum permeability through 
different mechanisms. They may act on the desmosomes, a kind of proteic 
junctional complex localized spot-like on the lateral sides of the plasma 
membranes, forming cohesion between keratinocytes, or modify the intercellular 
lipid domains to reduce the barrier resistance of the bilayer lipids [16] (fig 1.12) but 
are often associated with higher skin irritation. 
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Fig. 1.12. Action of penetration enhancers within the intercellular lipid domain.[16] 
 
Chemical approaches have emphasized formulations that selectively disrupt lipid 
bilayer structures in the stratum corneum to avoid effects in the viable epidermis in 
order to prevent skin irritation. In this way, the increase of permeability is limited 
to SC but does not address the barrier of the full epidermis, reducing release 
efficiency.[17] 
Active methods, like electroporation and iontophoresis, increase the transport 
across the skin by physically disrupting the barrier or using a driving force for drug 
transport, through an external energy source. 
In particular, electroporation creates a transitory structural perturbation of lipid 
bilayer membranes due to the application of high voltage impulses. The electrical 
stimulus causes a reorganization in cellular membrane, whereby phospholipids 
shift their position opening pores which act as conductive pathway through the 
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bilayer as they are filled with water (fig. 1.13). The creation of pores induces a high 
but reversible increase in transmembrane transport. 
 
  
Fig. 1.13. (Left) Schematic representation of electroporation system; (Right) Theoretical 
arrangement of lipids after electrical pulse showing a hydrophobic pre-pore (up) and a hydrophilic 
pore (down). 
 
Iontophoresis, instead, uses an electric field to move charged substances, usually a 
medication or a bioactive agent, through the skin by repulsive electromotive force. 
A small electric current is applied to an iontophoresis chamber placed on the skin, 
containing a charged active agent and its solvent; another electrode carries the 
return current (fig 1.14). The positively charged chamber, the cathode, will repel a 
positively charged chemical species into the skin, whereas negatively charged 
substances are collected on the anode. These devices are equipped with a power 
supply, which adds to the cost and the complexity of the treatment, and requires the 
passage of current in the patient‘s body, resulting annoying or even painful for 
them.[18] Furthermore, both these methods need the presence of trained sanitary 
personnel. 
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Fig 1.14. Scheme of the iontophoresis system. 
 
Another active method is liquid jet injection, which use a high-speed jet to 
puncture the skin and deliver drugs without the use of a needle (fig. 1.15).  
Jet injectors can be broadly classified into multi-use nozzle jet injectors (MUNJIs) 
and disposable cartridge jet injectors (DCJIs), depending on the number of 
injections carried out with a single device. 
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Fig 1.15. Schematic depiction of the jet injection process. A) Impact of a piston on a liquid reservoir 
in the nozzle increases the pressure, which shoots the jet out of the nozzle at high velocity (velocity 
>100 m s–1). B) Impact of the jet on the skin surface initiates formation of a hole in the skin 
through erosion, fracture or other skin failure modes. C) Continued impingement of the jet increases 
the depth of the hole in the skin. If the volumetric rate of hole formation is less than the volumetric 
rate of jet impinging the skin, then some of the liquid splashes back towards the injector. D) As the 
hole in the skin becomes deeper, the liquid that has accumulated in the hole slows down the 
incoming jet, and the progression of the hole in the skin is stopped. 
 
Liquid jet injections for immunization were first carried out using MUNJIs, which 
allowed repeated injections of vaccine from the same nozzle and reservoir at a rate 
of up to 1,000 immunizations per hour. They were successfully adopted for rapid 
mass immunization using vaccines against a large number of diseases, including 
measles, smallpox, cholera, HBV, influenza and polio.[19] But because the 
problems of cross-contamination, due to splash back of interstitial liquid from the 
skin onto the nozzle, the kind of treatment moved to the use of DCJIs that have 
sterile orifice and nozzle and is discarded between patients. All these systems 
increase skin permeability by disrupting or altering temporary structure of stratum 
corneum. Unfortunately, once the drug delivery is completed, it takes several hours 
or days to recover its integrity and this cause discomfort to the patient and can 
increase risk of infections specially if the treated area is extended.[20] 
Therefore, there is still a need for an ideal transdermal drug delivery system that a) 
is safe by maintaining skin permeability only during the desired period of drug 
delivery, b) can create sustained or bolus delivery profiles, c) can deliver 
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therapeutic volumes/doses of drug quickly with minimal discomfort, d) has rapidly 
responsive pharmacokinetics and pharmacodynamics, e) causes minimal pain and 
irritation, and f) is simple, inexpensive, and self-administrable.[21] 
All the requirements listed above seem to be satisfied by using microneedles. These 
devices are needles of micron dimension, able to puncture the stratum corneum, as 
to create microchannel that allow also the passage of hydrophilic macromolecules, 
without stimulation of nerves ending in dermis. Details concerning microneedles 
properties, materials and fabrication techniques are reported in the following 
chapter. 
1.3 Microneedles 
A microstructured transdermal drug system, consists of an array of microstructured 
projections, called microneedles, that are applied to the skin to provide intradermal 
delivery of active agents, which otherwise would not cross the stratum corneum. 
Such microneedles can be used for different kinds of drug delivery. One of the first 
developed microneedle based devices – and is still used nowadays - was mainly 
intended to be applied to the skin prior to topical administration of a medicament. 
This device comprises microneedles typically made of metal, with the aim to 
provoke a temporary mechanical disruption of the skin so that the stratum corneum 
can be effectively crossed by the medicament. Microneedles are somewhat like 
traditional needles, but are fabricated on the micro scale. They are generally 
hundreds microns in length. Microneedles have been fabricated with various 
materials mainly including polymers. A microneedle is thus smaller than a 
hypodermic needle, does not hurt when it pierces the skin and offers several 
advantages when compared to conventional needle technologies. Microneedles are 
specifically designed in order to cross the stratum corneum, which as mentioned is 
the outer layer of the skin, but being short enough to avoid the puncture of nerve 
endings. Conventional needles which do pass this layer of skin may effectively 
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transmit the drug but may lead to infection and pain, since they are much longer. 
Various types of microneedles have been fabricated such as solid (straight, bent, 
filtered), and hollow. Microneedles can also be coated with a drug typically using a 
water-soluble formulation. In this case, after insertion of microneedles into the 
skin, the drug coating is dissolved off into the skin, after which the microneedles 
are removed. Alternatively, microneedles can be made completely out of water-
soluble or biodegradable polymer which encapsulates the drug within the 
microneedle matrix. In this way, the microneedles completely dissolve or degrade 
in the skin, thereby releasing the encapsulated drug payload and leaving behind no 
sharps waste, since microneedles have dissolved away. 
Different active molecules, such as vaccines or diagnostic agents, can be delivered. 
In addition, other tissues besides the skin can be targeted, such as the eye. 
Hollow microneedles can be used with drug patches and timed pumps to deliver 
drugs at specific times. Arrays of hollow microneedles can be used to continuously 
carry drugs into the body using simple diffusion or a pump system. Hollow 
microneedles can also be used to remove fluid from the body for analysis – such as 
blood glucose measurements – and to supply microliter volumes of insulin or other 
drug as required. 
The hollow needle designs include tapered and beveled tips, and could eventually 
be used to deliver microliter quantities of drugs to very specific locations. An array 
of 400 microneedles has recently been used to pierce human skin for delivering 
macromolecular drugs. Very small microneedles could provide highly targeted 
drug administration to individual cells. These are capable of very accurate dosing, 
complex release patterns, local delivery and biological drug stability enhancement 
by storing in a micro volume that can be precisely controlled. 
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1.3.1 Solid microneedles 
The fabrication of solid microneedles has been pursued to provide sufficient 
mechanical strength through choice of the proper material and geometry and to 
reduce the force needed to insert microneedles into tissue by increasing tip 
sharpness. 
1.3.1.1 Silicon microneedles 
Short silicon microneedles have been prepared using a silicon dry-etching process 
based on reactive ion etching with a chromium mask,[22, 23] as well as isotropic 
etching in an inductively coupled plasma etcher.[24] An isotropic wet etching of 
crystalline silicon using an alkaline solution has also been utilized to obtain solid 
microneedles.[25-27] Wet etching methods can lower fabrication costs compared to 
dry etching, but the geometry of microneedles is restricted by anisotropic etching 
along crystal planes by the KOH etchant.[28] To overcome this limit of wet 
etching, isotropic dry etching and anisotropic wet etching methods have been 
combined.[24] As an alternative approach, microneedles have been fabricated to 
serve as neural probes by dicing a silicon substrate to create a grid pattern of deep 
grooves and then acid etching the resulting pillars to create sharpened probe 
tips.[29-32] 
 
 
Fig 1.16. Silicon microneedles [26] 
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1.3.1.2 Metal microneedles 
Metal microneedles have been prepared by three-dimensional laser ablation,[33, 
34] laser cutting,[35] wet etching,[36, 37] and metal electroplating methods.[38, 
39] Rows of solid metal microneedles were fabricated directly, whereas two-
dimensional arrays of microneedles have been made by cutting microneedles into 
stainless steel and titanium metal sheets and then bending them at a 90° angle out 
of the plane of the sheet. Two-dimensional metal microneedles have also been 
prepared by depositing metal onto positive or negative microneedle molds by 
means of electroplating or electro less plating.[38] 
 
 
Fig.1.17. SEM image of Metal microneedles Micropoint Technologies. 
1.3.1.3 Ceramic microneedles 
Ceramic microneedles have been fabricated using ceramic micro molding and 
sintering. Solid ceramic microneedles were prepared by micromolding an alumina 
slurry using a PDMS microneedle mold and ceramic sintering.[40] Ceramic 
microneedles have also been made lithographically using a two-photon induced 
polymerization approach. A focused laser was scanned within a photosensitive 
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polymer–ceramic hybrid resin using a galvano scanner and a micro positioning 
system to induce polymerization locally in the shape of the microneedles.[41-43] 
 
 
Fig.1.18. SEM image of Ceramic microneedles[44]  
  
1.3.1.4 Polymeric microneedles 
One of the main problems with metallic and silicon microneedles is the accidental 
breakage of the needle inside the skin, since the organism is not able to remove 
them. For this reason, it is preferred to use biodegradable or dissolvable materials. 
Certain types of polymers have optimal properties, as biocompatibility, 
biodegradability and mechanical strength, to be used for realization of 
microneedles. Some of these, like poly(lactic-co-glycolic) acid (PLGA), poly-lactic 
acid (PLA),[45] carboxymethyl cellulose (CMC),[46] polyvinylpyrrolidone 
(PVP),[47] are already widely used for these applications. By changing polymer 
matrix, or using a double inclusion, i.e. drug in nano/microparticles incorporated in 
microneedles, it is possible to manage drug release kinetics and drive the drug to 
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the target site. Generally, polymer microneedles are prepared by replica molding in 
PDMS stamps obtained on polymer masters typically made by photolithography 
using optically curable polymers, which are then typically employed as master 
structures for replication by molding. 
The classical method to produce polymeric microneedles is a multistep process. 
There are three phases: 1) manufacturing of a master; 2) mold production; 3) 
replica molding of the final polymeric device. 
An example is the ultraviolet (UV)-curable polymer SU-8 which has been used 
extensively to fabricate microneedles.[48-50] 
A common UV lithography process, using SU-8, is illustrated in fig. 1.19. The 
substrate is coated with few hundred microns of photoresist deposited with the spin 
coating technique that is afterwards soft baked in order to remove the solvent and 
improve resist-substrate adhesion. UV lithography consists in radiating a 
photoresist through a chrome mask. In particular, using a mask with an array of 
circular or square dots it is possible to obtain microstructures having the shape of 
needles. After irradiation, a post-exposure bake is performed to increase the cross-
linking degree of the irradiated areas and stabilize them against the action of 
solvents during the development step. The development is performed immersing 
the substrate in propylene glycol methyl ether acetate at room temperature, 
followed by a rinsing step in water or isopropanol.[51] 
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Fig. 1.19. Photolithography standard protocol to create SU-8 master molds.[52] 
 
By using a combination of microlenses on a glass substrate and inclined rotation of 
the substrate, the path of UV light through the SU-8 was made to taper, thereby 
deﬁning microneedle structures with sharp tips. PMMA has also been used to make 
microneedle arrays employing an inclined deep X-ray exposure and vertical X-ray 
exposure known as the lithography, electroplating and molding (LIGA) 
technique.[53, 54] Using these approaches, microneedles can be fabricated as tall 
as a few millimeters with a high aspect ratio using standard contact lithography 
equipment due to the low optical adsorption of the polymers in the UV range of 
390 nm. 
A two photon initiated polymerization method has also been used to fabricate 
three-dimensional microstructures including microneedles. In this approach, a near 
39 
 
infrared ultra-short pulsed laser was focused into a photocurable resin to form 
three-dimensional microstructures using as sequential layer-by-layer fabrication 
technique.[55-57] 
These UV-curable polymers have been used primarily as master structures for 
making to create molds with successive preparation of the PDMS molds. 
Polyvinylalcohol (PVA), silicon and aluminum have also been used as mold 
materials to replicate polymer microneedles.[58, 59] The mold can then be ﬁlled at 
elevated temperatures with a molten thermoplastic material such as polycarbonate 
[54] and PMMA [60] to produce non degradable microneedles upon cooling and 
solidiﬁcation. 
Usually, if a thermo-plastic polymer like PLGA chosen, first PDMS stamp is 
loaded with a solution containing the drug or the encapsulated drug. Evaporation of 
the solvent leaves solid drug particles partially filling the mold; residual particles 
remaining on the surface of the mold can be removed using adhesive tape, and 
then, after drying, the polymer is melted on the stamp, that is filled with the help of 
vacuum. The mold is afterwards recovered with powder of biocompatible polymer 
and placed in a vacuum oven. Vacuum is necessary to remove entrapped bubble 
and helps to pull the polymer melt into the grooves of the mold (fig 1.20). 
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Fig. 1.20. Method to fabricate polymer microneedles that encapsulate drug for controlled 
release.[61] 
 
As shown in fig 1.21, this procedure gives an inhomogeneous distribution of drug 
inside the needle. Indeed, the most of it is accumulated towards the tip, and this, 
even if entail release of entire amount of drug, implies a fast release. 
 
 
Fig. 1.21. Polymer microneedles bevel-tip (left) and tapered-cone (right) made of PLGA and 
encapsulating calcein within their tips.[61] 
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Although this fabrication method is very simple and cheap, it is not suitable for all 
drugs. Indeed, generally, thermoplastic polymers with enough mechanical strength 
for this application, require a high melting temperature, that is incompatible with a 
wide drug‘s variety. 
On the other hand, photocurable polymers, like PEG and PVP, liquid before 
reticulation, or hydrogels modeled starting from aqueous solutions can also be 
used. In this case it is easier to mix the drug directly in the polymer matrix, 
obtaining a homogeneous distribution. By loading model drug into dissolving 
microneedles in different ways, one is able to design systems that can achieve rapid 
or extended release from a microneedle patch. Drug can be selectively incorporated 
into the microneedles themselves and not into the backing layer. A small volume of 
solution with drug is cast into the holes of the micromold to form microneedles. 
After wiping off excess solution from the micromold surface, polymer without 
drug is added onto the micromold and solidified. To administer larger drug doses 
as an extended release over at least hours, drug can be incorporated into both the 
microneedles and backing layer or, alternatively, just the backing layer[46] (fig 
1.22). 
 
 
  (a)      (b)            (c) 
Fig. 1.22. (a) Schematic representation of drug loaded in the entire device‘s volume, (b) into 
microneedles and (c) in back layer but not in microneedles[46]. 
 
The advantage of this approach is to obtain in a very simple way an array with 
hundreds of microneedles, all with the same shape. This process is also easily 
scalable to an industrial level further lowering the cost, for this reason several 
research groups have focused their attention on these methods, trying to improve 
efficiency. Chu, Choi and Prausnitz have developed a system to insert an air bubble 
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in the base of microneedles to concentrate drug towards needle‘s tip, as to 
minimize drug wastage. Moreover, they have incorporated a pedestal at the base of 
microneedles in order to insert tips more fully in the skin. More complete insertion 
of the microneedles allowed a higher fraction of the encapsulated drug to be 
delivered.[62] In some cases, because of long degradation time of PLGA, 
microneedles arrays are designed in order to leave tips inside skin, so drug release 
can continue after removal of the supporting patch, to reduce patient nuisance.  
This is possible coupling PLGA needles with a polymeric base quickly 
dissolvable,[63, 64] pushing arrowhead needles inside skin with metal shaft[64] or 
creating complex structure that rest stuck in tissue.[65] In other cases they are used 
hydrogel microparticles that by means of a swelling mechanism, cause 
microneedles breakage and acceleration of drug release.[66] Recently a novel 
drawing lithography technique has been proposed,[67, 68] such process free from 
replica moulding creates 3D microstructures from 2D thermosetting polymers, the 
difficulties of this technique are the high temperature, and the poor reproducibility 
due to the dynamic interaction between frame and fluid. 
Another novel non-contact and room temperature electro-drawing (ED) process for 
the direct and rapid fabrication of biodegradable microneedles by means of an 
electrohydrodynamic (EHD) process has been proposed,[69] this technique consists 
of drawing the microneedles from a sessile drop of a biopolymer solution by using 
EHD forces.   
In general, a variety of biodegradable and water-soluble polymers have been micro 
molded primarily to encapsulate drugs within the microneedle matrix for 
subsequent release in the skin. Polymer microneedles should be developed to 
completely degrade/dissolve in the skin and thereby leave behind no biohazardous 
sharps waste after use. 
These microneedles are typically made solely of safe, inert, water-soluble 
materials, such as polymers and sugars that will degrade/dissolve in the skin after 
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insertion. The most frequently used matrix materials are sodium hyaluronate, that is 
naturally present in the skin, and sodium carboxymethylcellulose.[70-75] 
Both are approved as inactive materials by FDA for parenteral drug products. Other 
materials include poly(vinylalcohol) (PVA),[76] poly(vinylpyrrolidone) (PVP),[77] 
methylvinylether-co-maleic anhydride (PMVE/MA) (Gantrez AN-139®) [78, 79] 
and low molecular weight sugars like maltose[80, 81] and trehalose [82]. 
Microneedles have also been prepared from biodegradable polymers such as 
polylactic-co-glycolic acid (PLGA)[80] polylactic acid (PLA) [83] and 
polyglycolic acid (PGA).[45] 
However, due to their slow dissolution rate in skin and a preparation method using 
high temperatures[63] or organic solvents, these polymers are less suitable as 
matrix material. They can be used as a skin pretreatment to increase permeability. 
Most of the dissolving microneedles in the literature need to be inserted into skin 
for at least 5 min to fully dissolve. In contrast, biodegradable polymer 
microneedles must be inserted and remain in the skin for at least several days to 
effectively utilize their controlled-release degradation properties to provide 
controlled release delivery in skin for up to months.[61] To shorten this time, arrow 
head microneedles were designed to separate from the shaft within seconds and 
remain embedded in the skin for subsequent dissolution.[64] 
Microneedles encapsulating hydrogel microparticles were also designed for 
successful separation of microneedles within less than 1 h of insertion into skin by 
swelling of the hydrogel microparticles.[66]  
Because microneedles may not insert fully into skin, it is sometimes desirable to 
encapsulate drugs only in the microneedle tips. For this purpose, drug has been 
localized in microneedle tips by forming multi-layered microneedles using 
sequential applications of different compositions of polymer solutions [84] and 
using a particle-based molding method.[65] Drug was also localized in tips by the 
addition of an air bubble at the base of each microneedle during fabrication, which 
prevented drug diffusion from the microneedles into the patch backing.[62] 
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Fig. 1.23. SEM image Polymeric microneedles. [45] 
Different types of cargos have been used including almost all vaccine types, 
ranging from peptides and proteins [70-72] to DNA vectors encoding antigenic 
proteins [75, 85, 86] and attenuated or inactivated viruses.[73, 87, 88] Antigens are 
generally dispersed directly in the Microneedles matrix[70-74] but they can also be 
encapsulated in nanoparticles or in a cross-linked structure [63, 89, 90] to 
potentiate or alter the immune response.[63, 89, 91] Furthermore, adjuvant can be 
incorporated in the Microneedles [92]. 
1.4 Applications 
The ability of microneedles to release efficiently both small and large molecules 
has encouraged studies for various applications. 
Several studies, regarding vaccination through microneedles for influenza,[64, 93] 
and Hepatitis B,[94] have demonstrated that with this new method is obtained a 
clinical response higher than hypodermal injection [95] using a lower drug 
dosage.[96] Also for other bioactive macromolecules, like insulin, heparin and 
growth hormone, that cannot be delivered orally because of proteolitic degradation, 
microneedles represented a valuable alternative. Zosano Pharmahas developed a 
parathyroid hormone coated microneedle patch system that is now under phase-3 
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clinical trial. These patches show an ideal plasma profile, indicative of efficient 
parathyroid hormone therapy in osteoporosis using microneedles.[97] 
Another, less common, application is drug delivery into eyes through sclera, 
fibrous membrane containing eyeball, for glaucoma treatment. This administration 
route has been proved to be more effective than topical administration or systemic 
delivery.[98] 
Also in cosmetic and cosmeceutical fields the majority of products can lend 
themselves to microneedles technology. So it is possible to apply release through 
microneedles for treatment against ageing (wrinkles, lax skin), scarring (acne, 
surgical), photodamage and hyperpigmentation (age/brown spots).[98, 99] 
Microneedles can be used, not only to administer drugs, but also to withdraw body 
fluids for diagnostic purposes. An example is blood withdrawal for glucose 
estimation: in this way it is possible to reduce blood sample required while making 
the procedure painless.[100] 
1.5 Limits of most diffused fabrication methods 
The production of polymeric microneedles has not diffused yet because the 
techniques illustrate beforehand show many limits and difficulties. 
The polymer microneedles produced with stamp-based methods have high costs, 
because are multi steps process, that require much time for the production. 
Also the selection of polymer is important because the microneedles must have a 
sufficient strength to penetrate the skin,[45, 101] and for this reason only high 
molecular weight polymers can be used. 
The production of polymer microneedles usually involves high temperature and 
that limit the use of  thermolabile drugs.[45, 61] 
The solvent casting at room temperature is a complex and long procedure.[46, 102] 
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Casting at room temperature of photocurable polymers has been proposed,[47, 103] 
but UV can impair the activity of the incorporated drug, and photoiniziators are 
potentially toxic.[104] 
In this wide scenario is set the present work, aimed at the production of polymeric 
microneedles that can overcome all the limitations deriving from the micro-casting 
and the drawing lithography approach, avoiding the use of high temperatures, 
multi- step filling process and hazardous UV are required. 
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Chapter II 
 
Experimental section 
 
In this work a new fabricated-mold-based method to create polymeric and 
biodegradable microneedles is discussed. The fabrication of microneedles starts 
with the realization of a master with different microfabrication techniques, 
followed by the production of polymeric microparticles. In particular, the attention 
has been focused on PLGA as polymer for the production of microparticles. The 
innovation is to produce microneedles deforming the fabricated microspheres under 
gentle process conditions (i.e. at room temperature by using a solvent/non-solvent 
vapor mixture). 
2.1 Material 
Poly (lactic-co-glycolic acid) 50:50 (PLGA RESOMER® RG 504H), 38000 -
54000 Dalton, was purchased by Boeringer Ingelheim and used as received. 
Polyvinylpyrrolidone (PVP 856568 Mw 55 KDa) Dimethyl Carbonate (DMC, 
D152927), as solvent of the PLGA, as well as all the chromophores used as model 
drug, Sulpho Rhodamine  (SulphoRh6G, S470899) and Paraffin wax (327204) 
were purchased by Sigma Aldrich. Poly (dimethyl-siloxane) (PDMS), used as 
flexible support, was provided by Sylgard® (184 Silicone Elastomer Kit, Dow 
Corning). Pig skin was kindly provided by dott.ssa Antonelli Carmela of ASL 
Napoli 2 Nord, taken from the butchery implant ICS (Industria Carni Sud) of 
Caivano, Naples (IT). 
2.1.1 Poly (lactic-co-glycolic acid) 
PLGA is one of the most successfully developed biodegradable polymers. Among 
the different polymers developed to formulate polymeric microparticles, PLGA has 
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attracted considerable attention due to its attractive properties: (i) biodegradability 
and biocompatibility, (ii) FDA and European Medicine Agency approval in drug 
delivery systems for parenteral administration, (iii) well described formulations and 
methods of production adapted to various types of drugs e.g. hydrophilic or 
hydrophobic small molecules or macromolecules, (iv) protection of drug from 
degradation, (v) possibility of sustained release, (vi) possibility to modify surface 
properties and/or better interaction with biological materials and (vii) possibility to 
target nanoparticles to specific organs or cells. The high biodegradability of PLGA 
is related to its hydrolysis that leads to metabolic monomers, lactic acid and 
glycolic acid (fig.1) since these two monomers are endogenous and easily 
metabolized by the body via the Krebs cycle, and a minimal systemic toxicity is 
associated with the use of PLGA for drug delivery or biomaterial applications. The 
polymers are commercially available with different molecular weights and 
copolymer compositions. The degradation time can vary from several months to 
several years, depending on the molecular weight and copolymer ratio.[1, 2] The 
forms of PLGA are usually identified by the monomers ratio used. For example, 
PLGA 50:50 identifies a copolymer whose composition is 50% lactic acid and 50% 
glycolic acid. Poly (lactic acid) (PLA) has also been used to a lesser extent than 
PLGA due to the lower degradation rate. 
 
Fig. 2.1. Structural formula of PLA, PGA and their copolymer PLGA. 
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According to the ratio of lactide to glycolide used for the polymerization, different 
forms of PLGA can be obtained: these are usually identified in regard to the 
monomers‘ ratio used (i.e., PLGA 75:25 identifies a copolymer consisted of 75% 
lactic acid and 25% glycolic acid). Different synthesis mechanisms are used to 
obtain PLGA and the process parameters influence strongly the physical-chemical 
characteristics of the end product. 
The PLGA can be used in various biomedical applications, i.e., in drug delivery, 
where the drug/biomolecule kinetic release is dramatically influenced by the 
polymeric degradation rate. 
PLGA degrades by hydrolysis of its ester group, through bulk or heterogeneous 
erosion, in aqueous environments. 
In details, the degradation path can be divided in four steps:  
 hydration: water penetrates into the amorphous region and disrupts the van 
der Waals forces and hydrogen bonds, causing a decrease in the glass 
transition temperature (Tg);  
 initial degradation: cleavage of covalent bonds, with a decrease in the 
molecular weight;  
 constant degradation: carboxylic end groups auto-catalyze the degradation 
process, and mass loss begins by massive cleavage of the backbone 
covalent bonds, resulting in loss of integrity;  
 solubilization: the fragments are further cleaved to molecules that are 
soluble in the aqueous environment.[3] 
The Tg of PLGA is reported to be above 37 °C and, hence, PLGA has a glassy 
behavior in nature, showing fairly rigid chain structure. 
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2.1.2 Polyvinylpyrrolidone 
Polyvinylpyrrolidone (PVP), also commonly called polyvidone or povidone, is a 
water-soluble made from the monomer N-vinylpyrrolidone.[4] 
 
Fig. 2.2. Structural formula of VP and PVP. 
PVP is also used in many technical applications: 
 as an adhesive in glue stick and hot-melt adhesives 
 as a special additive for batteries, ceramics, fiberglass, inks, and inkjet paper, 
and in the chemical-mechanical planarization process 
 as an emulsifier for solution polymerization 
 to increase resolution in photoresists for cathode ray tubes (CRT)  
 in aqueous metal quenching 
 for production of membranes, such as dialysis and water purification filters 
 as a binder and complexation agent in agro applications such 
as crop protection, seed treatment and coating 
63 
 
 as a thickening agent in tooth whitening gels[5] 
 as an aid for increasing the solubility of drugs in liquid and semi-liquid dosage 
forms (syrups, soft gelatin capsules) and as an inhibitor of recrystallization 
 as an additive to Doro's RNA extraction buffer 
 as a liquid-phase dispersion enhancing agent in DOSY NMR [6] 
 as a surfactant, reducing agent, shape controlling agent and dispersant in 
nanoparticle synthesis and their self-assembly[7]. 
The U.S. Food and Drug Administration (FDA) has approved this chemical for 
many uses, and it is generally considered safe. 
PVP is soluble in water and other polar solvents. For example, it is soluble in 
various alcohols, such as methanol and ethanol,[8]
[
 as well as in more exotic 
solvents like the deep eutectic solvent formed by choline 
chloride and urea (Relin).[9] When dry it is a light flaky hygroscopic powder, 
readily absorbing up to 40% of its weight in atmospheric water. In solution, it has 
excellent wetting properties and readily forms films. This makes it good as a 
coating or an additive to coatings.  
PVP was first synthesized by Walter Reppe and a patent was filed in 1939 for one 
of the most interesting derivatives of acetylene chemistry. PVP was initially used 
as a blood plasma substitute and later in a wide variety of applications in medicine, 
pharmacy, cosmetics and industrial production.[7, 10]  
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2.2 Microspheres of PLGA 
Single emulsion process: Oil-in-water emulsification processes are examples of 
single emulsion processes. Polymer in the appropriate amount is first dissolved in a 
water immiscible, volatile organic solvent (e.g, dichloromethane (DCM)) in order 
to prepare a single phase solution. The drug of particle size around 20–30 μm is 
added to the solution to produce a dispersion in the solution. This polymer 
dissolved drug dispersed solution is then emulsified in large volume of water in 
presence of emulsifier (polyvinyl alcohol (PVA) etc.) in appropriate temperature 
with stirring. The organic solvent is then allowed to evaporate or extracted to 
harden the oil droplets under applicable conditions. In former case, the emulsion is 
maintained at reduced or atmospheric pressure with controlling the stir rate as 
solvent evaporates. In the latter case, the emulsion is transferred to a large quantity 
of water (with or without surfactant) or other quench medium to diffuse out the 
solvent associated with the oil droplets. The resultant solid microspheres are then 
washed and dried under appropriate conditions to give a final injectable 
microsphere formulation.[11-14] Double (Multiple) emulsion process: Water-in-
oil-in-water emulsion methods are best suited to encapsulate water-soluble drugs 
like peptides, proteins, and vaccines, unlike single emulsion methods which is ideal 
for water-insoluble drugs like steroids. First, an appropriate amount of drug is 
dissolved in aqueous phase (deionized water) and then this drug solution is added 
to organic phase consisting of PLGA and/or PLA solution in DCM or chloroform 
with vigorous stirring to yield a water-in-oil emulsion. Next, the water-in-oil 
primary emulsion is added to PVA aqueous solution and further emulsified for 
around a minute at appropriate stress mixing conditions. The organic solvent is 
then allowed to evaporate or is extracted in the same manner as oil-in-water 
emulsion techniques. In double emulsion processes, choice of solvents and stirring 
rate predominantly affects the encapsulation efficiency and final particle size.[11, 
15, 16] 
65 
 
In this work PLGA microspheres were obtained through the double emulsion 
process fig.2.3.  
 
Fig.2.3. Schematic diagram of double emulsion techniques.[17] 
The polymer was dissolved in DCM, in order to obtain the dispersed phase of 
emulsion, while for the continuous phase it was used the (polyvinyl alcol) PVA.  
2.2.1 Production process 
For the preparation of the solution consisting of the discontinuous phase, 100 mg of 
polymer (83 mg of PLGA and 17 mg of Pluronic F68) were dissolved in 1 ml of 
solvent dichloromethane (DCM), while 0.55 mg of Sulforhodamine B was 
dissolved 1 ml of water. 100 µl of the latter solution was added to the former. The 
emulsification process was performed with the Ultra-turrax that is a homogenizer. 
The first emulsion has been prepared for 30 s at 15000 rpm and added to the 
continuous aqueous phase based on 10 ml of PVA solution (at 2% w/v). Second 
emulsion has been carried out always with the same instrument for 1 min at 20000 
rpm. After that, the solution is kept under mechanical stirring for about 2 h and 30 
II step 
I step 
Water 
Particles in emulsion PVA 
W1/O emulsion Polymer in 
DCM  
W1/O  
66 
 
min, at a speed of 450 rpm, to remove completely the polymeric solvent trough 
evaporation method. The microparticles are rinsed with deionized water to remove 
the PVA from the solution with 3 centrifuges of 10 min at 15000 rpm. For their 
conservation, they are filtered from the water, frozen at – 80°C for 15 min and then 
subjected to freeze-drying over-night. 
2.3 Master production 
The techniques used for the production of microneedle is a stamp based method, 
for this reason an important aspect is to create a master with a good shape to allow 
the indentation in the skin. Microfabrication technology has traditionally been used 
to produce master of microneedles. In the early years, the fabrication technology 
for silicon based structures has been focused on lithography, etching, and 
deposition. Besides IC based methods, other fabrication processes such as 
micromolding, wire electro discharge machining, laser machining, ion and electro-
beam machining and dicing were also exploited for miniaturization.[18] The 
surface micromachining and bulk micromachining are the two branches of 
microfabrication techniques. Surface micromachining is an addictive process, 
which consists of the fabrication of microstructure from deposited thin films.[19] 
The bulk micromachining is a subtractive process that uses the  selective removal 
of materials from substrate to form microstructures.[20] 
More recently, the microfabrication technology has been increasingly used to 
machine micro-scale devices related to biological applications.[21, 22] 
Compared to the numerous biological applications such as biosensors and fluidic 
microdevices for sample separation, the use of microfabrication in the drug 
delivery has been limited. One potential approach was to use microneedles to 
achieve optimum therapeutic effect for new drugs. With the application of 
advanced microfabrication technology, novel microdevices may be fabricated to 
fulfill the requirements for drug delivery. One example is based on microneedles 
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with a good shape and a sharp tip (1÷10 µm), which increases the mechanical 
strength needed to support polymer microneedles.[23, 24] 
2.3.1 2Photon Laser 
In recent years, two-photon lithography (TPL) has emerged as a powerful tool to 
create complex, small-scale 3D materials.[25-30] By focusing a femtosecond laser 
into a negative-tone photoresist, polymerization can be locally induced within the 
focal region of the beam. Rastering the laser focus throughout the photoresist in 
three dimensions then enables the creation of polymer structures with virtually any 
geometry.[31-33] This architectural versatility renders these 3D polymer structures 
useful for many technological applications, including drug delivery,[34-36] tissue 
engineering,[37-39] micro-nano-optics,[40, 41] and photonics.[42, 43] 
2.3.1.1 Photolithography process  
2PP was performed on a Nanoscribe Photonic Professional GT system (Nanoscribe 
GmbH). The Nanoscribe system uses a 780 nm Ti-Sapphire laser emitting ≈100 fs 
pulses at 80 MHz with a maximum power of 150 mW and is equipped with a 63x, 
1.4 NA oil immersion objective. The substrate is placed in a holder that fits into a 
piezoelectric x/y/z stage. A galvo scanner determines the laser trajectories. The oil-
immersion configuration the lens is immersed in oil with a refractive index 
matching that of the glass coated with the photoresist; here, because of the 
refractive index difference between the glass and the photoresist, a laser scattering 
takes place at the glass-photoresist interface then worsening the fabrication 
performances of the system. The negative tone IP-DIP photoresists assures a high 
resolution combined with simplicity of use and is optimized for the process of 
multiphoton polymerization. The IP photoresists are exclusively available to users 
of the Nanoscribe systems. In the fig. 2.4 a representation of geometrical array 
produced with 2 Photon laser different masters have been developed with same  
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shape but with different dimension. 
 
Fig. 2.4. Schematic representation of Microneedle array with conical shape. 
 
2.3.2 Laser 2D and ICP-RIE 
Less than 10 years ago, inductively coupled plasma (ICP) reactors have been 
introduced for silicon reactive ion etching (RIE) process leading to the deep 
reactive ion etching (DRIE) technique. The main novelties on these rather new 
ICP-RIE systems are the following: 
 separation of the main plasma from the wafer 
 a higher plasma density 
 improved Radio Frequency RF-power supply 
 improved performance for pumping and mass-flow systems 
 pulsed Low Frequency LF substrate biasing 
 new chemistry and new process (Bosch and cryogenic) 
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These hardware and process novelties led to improved performances, for instance: 
– Higher selectivity for deep etching 
– Higher aspect ratio (AR) 
– Higher etching rate, either for anisotropic or isotropic etching 
– Reduction of parasitic effects: notching, aspect ratio dependent Etching 
(ARDE), etc. 
The microfabrication of high aspect ratio microstructures (HARMS) is the main 
benefit of these technologies with numerous applications in the field of MEMS. 
There are two main ways of achieving HARMS by DRIE. The most popular way is 
the ‗Bosch process‘, a patented process developed by[44], which is based on 
alternating multiple steps of etching and sidewall passivation. The main alternative 
is the ‗cryogenic process‘, relying on cooling the stage and silicon to cryogenic 
temperatures using liquid nitrogen.[45, 46]  
2.3.2.1 Production master  
Silicon wafers with resistivity ranging from 1 to 10   cm, and thickness of 450 μm  
were used in this study. With use of a spin coater a layer of AZ4562 positive 
photoresist was deposited on the silicon wafer. Using a speed of 3000 rpm a 
photoresist layer of 8 μm was obtained. The spincoater employed was the WS-650 
Series (Laurell Technologies Corporation, USA). Then, after a postback at 100°C 
for 3 min, the wafer was used for photolithography treatment. The thickness was 
measured with a contact profilometer (Dektak Veeco 150). 
For the 2D lithography process we used a mask-less 2D lithography system 
(Heidelberg DLW-66FS) equipped with a Diode Laser, 405nm, 100mW. 2D laser 
was performed on a Heidelberg instrument. With 2D laser an array of circle with 
150 μm of diameter was fabricated. Then the sample was developed in a 4:1 water-
developer solution for 60 s, rinsed with water and dried with nitrogen; as developer 
we used the AZ 351-B (Microchemicals GmbH). 
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The patterned sample was etched with the inductively coupled plasma reactive ion 
etching technology (ICP-RIE); the system used here was the PlasmaPro 100 Cobra 
(OXFORD Instruments). 
Etching was performed until the oxide mask fell off due to the under etching, 
which generated the pyramidal needle structure. 
The structure of microneedle was fabricated by the mixed anisotropic and isotropic 
plasma etching in inductively coupled plasma (ICP) etcher.[47] The ICP high 
density plasma etcher is well known to carry out deep reactive ion etching (DRIE), 
implemented with BOSCH process, which utilizes an etching cycle using SF6 gas 
and then switches to a sidewall passivation cycle using C4F8 gas.[48] 
After the dry etching, the sample was immersed in acetone for the photoresist 
stripping, rinsed with 2-propanol and dried with nitrogen. To characterize the 
etching results the sample was analyzed by SEM (FESEM ULTRAPLUS ZEISS). 
In the fig. 2.5 a representation of geometrical array produced with 2D Laser and 
ICP-RIE different masters have been developed with same shape but with different 
dimension. 
Fig.2.5. Schematic representation of Microneedles array with pyramidal shaped tip cylinder.   
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2.4 PDMS mold 
Poly (dimethyl siloxane) (PDMS) is a silicon elastomeric polymer with many 
properties that make it excellent as material for biomedical application, namely 
optical transparency, chemical and biologically inertness, non-toxicity, 
permeability to gases and excellent mechanical resistance. 
The structure of PDMS is: 
 
 
 
Fig. 2.6. Structural formula PDMS. 
 
Several properties of PDMS are instrumental in the formation of high quality 
patterns: 
 PDMS is an elastomer and conforms to the surface of the substrate over a 
relatively large area 
 it is deformable enough such that conformable contact can even be achieved 
on surfaces that are non-planar on a micrometer scale 
 elastic characteristics of PDMS allows it to be released easily from complex 
and fragile structures 
 PDMS provides a surface with low interfacial free energy (21.6 * 10
-3
 Jm
-2
) 
and chemically inert 
 PDMS is homogeneous, isotropic and optically transparent down to 300 nm 
 PDMS is durable and the stamps can be used up to about 100 times over a 
period of several months without noticeable degradation. 
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 surface properties of PDMS can be modified by plasma treatment followed 
by the formation of SAMs (self-assembled monolayers) to give appropriate 
interfacial interactions with materials with a wide range of interfacial free 
energies.  
The reparation of PDMS start with the mixing of the precursor with the curing 
agent, generally in ratio 10:1, and kept under vacuum to remove entrapped air 
bubbles. To make microneedles molds, master structure arrays of microneedles in 
relief are coated with liquid PDMS precursor and allowed to cure in oven; from a 
single master it is possible to get several molds fig 2.7. 
 
 
Fig. 2.7. Schematic procedure for fabrication of PDMS stamp. 
 
After polymerization and cross-linking, solid PDMS presents a hydrophobic 
surface and this facilitates the separation from hydrophilic materials. 
It is possible to make PDMS hydrophilic by adding to the PDMS precursor and 
treating agent mixture a surfactant i.e. SILVET in ratio 100:1. 
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Thus PDMS structure can be used in combination with water and alcohol solvent 
without material deformation. 
2.5 Polymeric microneedles 
Two different processes have been used for the production of microneedles array, 
obtained through the use of a stamp based process assisted by solvent. 
The first process can be divided in three steps:  
1. microparticles inserted in the stamp;  
2. PLGA microparticles sintered with a room temperature process, with a 
solvent not solvent mixture; 
3. hydrophilic matrix deposition. 
The second process can be divided in four steps: 
1. production of microneedles tips with hydrophilic polymer through degasing 
and spinning; 
2. microparticles inserted in the stamp;  
3. PLGA microparticles sintered with a room temperature process, with a 
mixture of solvent not solvent; 
4. deposition of hydrophilic polymer on the medical tape.  
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2.5.1 Solvent evaporation  
Solvent evaporation was performed with a Drechsel Bottle. 
 
Fig. 2.8. Scheme of the Drechsel Bottle. 
The mixture of solvent is put inside the bottle with a stream of nitrogen flow that 
produces bubbles. It was possible to control the pressure of nitrogen flow through a 
pressure regulator. 
The plasticizing vapor product arrived on the substrate through a tube. The drechesl 
bottle was connected to a thermostatic bath, which is used to maintain constant the 
temperature of the inlet heating liquid. 
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Fig. 2.9. System used for the plasticization of the microspheres. 
2.5.2 Production process 
The solvent mixture was composed by 4 ml of ethanol and 0.5 ml of DMC. The 
temperature and the pressure were set respectively at 25.3°C and 0.15 bar. This 
condition is the same for both processes, and it is good for the softening of PLGA 
microparticles which have been used. 
In the first process the microspheres were disposed in the cavities of the PDMS 
mold, inserted whit the use of the microscope. 
In the second phase, the mold with the microspheres was placed under the tube in 
which the plasticizing vapor flows. After a few minutes it can be observed the 
plasticization of the microspheres that assume the shape of microneedles, and then 
a hydrophilic matrix is deposited on the mold. This method does not allow the 
production of a very sharp tip because it is difficult to insert correctly the 
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microspheres at the deeper part of the stamp cavities. For this reason, it has been 
implemented the second process. 
In this case the tip of microneedles is produced with a hydrophilic polymer inserted 
in the mold through degassing and then spinning. Then, in the second step similar 
to the process described previously microparticles were inserted in the cavities of 
the mold in order to produce the base of microneedles, and then  the mold was 
placed under the tube in which the plasticizing vapor flows. The plasticization of 
microparticles occurs after few minutes. Finally, in order to extract the 
microneedles from the stamp a 3M medical tape with a hydrophobic layer was 
used.  
2.6 Characterization of microneedles 
The microneedles were characterized with several analyses to study morphological 
aspect, distribution of drug and mechanical resistance. 
2.6.1 Multiphoton fluorescence microscopy 
The multiphoton fluorescence microscope (MPM) uses pulsed long wavelength 
light to excite fluorophores within the specimen being observed. The fluorophore 
absorbs the energy from two long-wavelength photons which must arrive 
simultaneously in order to excite an electron into a higher energy state, from which 
it can decay, emitting a fluorescence signal (fig. 2.10). It differs from traditional 
fluorescence microscopy in which the excitation wavelength is shorter than the 
emission wavelength, as the summed energies of two long wavelength exciting 
photons will produce an emission wavelength shorter than the excitation 
wavelength. 
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Fig. 2.10. Diagram indicating the absorption of two NIR photons to excite the fluorescent molecule 
to an excited state and the visible fluorescence emitted during relaxation. 
 
Multiphoton fluorescence microscopy has similarities to confocal laser scanning 
microscopy. Both use focused laser beams that scan the sample to generate images, 
and both have an optical sectioning effect. Unlike confocal microscopes, 
multiphoton microscopes do not contain pinhole apertures, which give confocal 
microscopes their optical sectioning quality. The optical sectioning produced by 
multiphoton microscopes is a result of the point spread function of all elements 
included in optical path, namely depends on how the system blurs the image of a 
bright spot formed where the pulsed laser beams coincide. 
Compared to similar optical imaging techniques, MPM holds inherent advantages 
for imaging living tissues by improving depth penetration and reducing 
photodamage. This is a direct result of employing near infrared (NIR) femtosecond 
lasers to generate observable nonlinear signals in the visible range. The NIR 
excitation enhances the ability to image deeper into a sample through a reduction 
light scattering proportional to the fourth power of the excitation wavelength. 
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2.6.2 Scanning Electron Microscope 
For morphological analysis of microneedles sectioned a field emission SEM (Ultra 
plus Zeiss) was used. A scanning electron microscope (SEM) is a type of electron 
microscope that produces images of a sample by scanning it with a focused beam 
of electrons. The electrons interact with atoms in the sample, producing signals that 
can be detected and that contain information about the sample's surface topography 
and composition. In a typical SEM, an electron beam is thermoionically emitted 
from an electron gun fitted with a tungsten filament cathode. The electron beam, 
which typically has an energy ranging from 0.2 keV to 40 keV, is focused by one 
or two condenser lenses to a spot about 0.4 nm to 5 nm in diameter. The beam 
passes through pairs of scanning coils or pairs of deflector plates in the electron 
column, typically in the final lens, which deflect the beam in the x and y axes so 
that it scans in a raster fashion over a rectangular area of the sample surface (fig. 
2.11). 
 
Fig. 2.11. Functioning scheme of a scanning electron microscope. 
When the primary electron beam interacts with the sample, the electrons loose 
energy by repeated random scattering and absorption within a region of sample‘s 
volume, whose extension depends on the electron's landing energy, the atomic 
number of the specimen and the specimen's density. The interaction between 
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electron beam and surface sample produce a great number of particles, like 
secondary electrons (SE), back-scattered electrons (BSE), characteristic X-rays and 
transmitted electrons. In the standard detection mode, secondary electron imaging 
or SEI, the SEM can produce very high resolution images of a sample surface. 
Instead, back-scattered electrons (BSE) are beam electrons that are reflected from 
the sample by elastic scattering. BSE are often used in analytical SEM along with 
the spectra made from the characteristic X-rays, because the intensity of the BSE 
signal is strongly related to the atomic number (Z) of the specimen. 
2.6.3 Chromophore distribution 
Different hydrophilic chromophores were used to produce microneedles, in order to 
study the distribution inside the microneedle. Microneedles were incorporated in 
PDMS, cured for 24 h at room temperature, and then frozen at -140 °C in Leica 
CryoUltra Microtome EM-FC7-UC7. Samples were sectioned at a thickness of 5 
μm for confocal analysis in axial direction. Slices of samples were analyzed with a 
confocal Leica TCS at 543 nm using a 20X air microscope objective. While 
cutting, slices tend to bend so they are not perfectly outstretched on cover glasses. 
For this reason, since the surface is not included entirely in the same focal plane, in 
order to acquire an entire slice, stack acquisitions were performed on thick layers 
using 0.5 μm Z-steps. The acquired images were collected and analyzed using 
ImageJ (Java-based image processing program developed at the National Institutes 
of Health) studying fluorescence profile in axial direction and transverse direction 
at certain distances from the tip, as show in fig. 2.12. 
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Fig. 2.12. Schematic direction illustration of section plane. 
2.6.4 Porosity 
The microneedles and microparticles were sectioned as described above at a 
thickness of 5 μm and a morphological analysis was performed using scanning 
electron microscope (SEM) (field emission Ultra plus Zeiss. This analysis allows 
understanding how the sintering process influences microneedles porosity. Samples 
were sputter coated with a 15 nm thick gold layer and to avoid any damage, a 
voltage (EHT) of 10 kV was imposed. Morphological analysis of porosity was 
carried out on the as produced microneedles. 
2.7 Mechanical characterization 
The fundamental requirement for microneedles is an adequate mechanical 
resistance, that allows to puncture the stratum corneum. For this reason, it is very 
important to study their capability to indent skin, in this way we demonstrate the 
mechanical properties of the microneedles. 
 
ORIZZONTAL SECTION VERTICAL SECTION 
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2.7.1 Indentations in skin 
First, indentation tests were performed in gelatin and paraffin wax. 
Thin layers were prepared using these materials, the test was conducted under 
stereomicroscope. In order to confirm that the indentation had occurred the layer of 
paraffin was replicated with PDMS prepared as previously described. 
Different arrays of microneedles with different dimensions were inserted in a full 
thickness cadaver pig skin without subcutaneous fat layer. The skin was shaved 
with depilatory cream and washed in a phosphate buffered saline (PBS) solution; 
finally, it was placed on absorbing paper for few minutes to eliminate the excess of 
water. Two different indentation tests were carried out with a SMICNA applicator 
system. 
 
 
Fig. 2.13. SMICNA Applicator system. 
 
In the first test, microneedles were removed after indentation and the skin was 
fixed in a solution of 10% neutral buffered formaline for 24 h, dehydrated in an 
incremental series of ethanol (75 %, 85 %, 95 % and 100 % and 100 % again, each 
step is performed for 30 min at room temperature) treated with two series of xylene 
for 30 min and then were embedded in paraffin.  
Successively, samples were sectioned at thickness of 3μm, and stained with 
hematoxylin and eosin, and finally the sections were mounted with Histomount 
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Mounting Solution (INVITROGEN) on coverslips and the morphological features 
of constructs were observed with a light microscope (BX53; Olympus). 
In the second test the skin was fixed in a solution of 10% neutral buffered 
formaline for 24 h. Samples were dehydrated by serial immersions, each of 30‘, in 
Methanol 50%, 70%, 80%, 90%, 100%, 100%. BABB solution was prepared 
containing Benzyl Alcohol (BA) and Benzyl Benzoate (BB) (SIGMA) in 1:2 ratio. 
Samples were moved into a glass bottle and treated with Methanol and BABB (1:1) 
for 4h and following with BABB for 24h at RT. Samples were investigated into 
fluorodish by Confocal Leica TCS SP5 II. 
  
83 
 
2.8 References 
 
[1] A. Prokop, J.M. Davidson, Nanovehicular intracellular delivery systems, 
Journal of pharmaceutical sciences 97(9) (2008) 3518-3590. 
[2] M. Vert, J. Mauduit, S. Li, Biodegradation of PLA/GA polymers: increasing 
complexity, Biomaterials 15(15) (1994) 1209-1213. 
[3] C. Engineer, J. Parikh, A. Raval, Review on Hydrolytic Degradation Behavior 
of Biodegradable Polymers from Controlled Drug Delivery System, Trends in 
Biomaterials & Artificial Organs 25(2) (2011). 
[4] F. Haaf, A. Sanner, F. Straub, Polymers of N-vinylpyrrolidone: synthesis, 
characterization and uses, Polymer Journal 17(1) (1985) 143-152. 
[5] T. Chen, Dental bleach, Google Patents, 2004. 
[6] J.S. Kavakka, I. Kilpel inen, S. Heikkinen, General chromatographic NMR 
method in liquid state for synthetic chemistry: polyvinylpyrrolidone assisted DOSY 
experiments, Organic letters 11(6) (2009) 1349-1352. 
[7] K.M. Koczkur, S. Mourdikoudis, L. Polavarapu, S.E. Skrabalak, 
Polyvinylpyrrolidone (PVP) in nanoparticle synthesis, Dalton Transactions 44(41) 
(2015) 17883-17905. 
[8] P. DeMarco, Polyvinylpyrrolidone Explained. 
[9] L. Sapir, C.B. Stanley, D. Harries, Properties of polyvinylpyrrolidone in a deep 
eutectic solvent, The Journal of Physical Chemistry A 120(19) (2016) 3253-3259. 
[10] F. Fischer, S. Bauer, Polyvinylpyrrolidon. Ein tausendsassa in der chemie, 
Chemie in unserer Zeit 43(6) (2009) 376-383. 
[11] R. Arshady, Preparation of biodegradable microspheres and microcapsules: 2. 
Polyactides and related polyesters, Journal of Controlled Release 17(1) (1991) 1-
21. 
[12] T.W. King, C.W. Patrick, Development and in vitro characterization of 
vascular endothelial growth factor (VEGF)‐loaded poly (DL‐lactic‐co‐glycolic 
acid)/poly (ethylene glycol) microspheres using a solid encapsulation/single 
84 
 
emulsion/solvent extraction technique, Journal of Biomedical Materials Research 
Part A 51(3) (2000) 383-390. 
[13] I.D. Rosca, F. Watari, M. Uo, Microparticle formation and its mechanism in 
single and double emulsion solvent evaporation, Journal of Controlled Release 
99(2) (2004) 271-280. 
[14] H. Sah, Microencapsulation techniques using ethyl acetate as a dispersed 
solvent: effects of its extraction rate on the characteristics of PLGA microspheres, 
Journal of Controlled Release 47(3) (1997) 233-245. 
[15] W. Chaisri, W.E. Hennink, S. Okonogi, Preparation and characterization of 
cephalexin loaded PLGA microspheres, Current drug delivery 6(1) (2009) 69-75. 
[16] S. Mao, J. Xu, C. Cai, O. Germershaus, A. Schaper, T. Kissel, Effect of WOW 
process parameters on morphology and burst release of FITC-dextran loaded 
PLGA microspheres, International journal of pharmaceutics 334(1) (2007) 137-
148. 
[17] D. Ibraheem, M. Iqbal, G. Agusti, H. Fessi, A. Elaissari, Effects of process 
parameters on the colloidal properties of polycaprolactone microparticles prepared 
by double emulsion like process, Colloids and Surfaces A: Physicochemical and 
Engineering Aspects 445 (2014) 79-91. 
[18] M.J. Madou, Fundamentals of microfabrication: the science of miniaturization. 
2002, ISBN-10 1208775268. 
[19] J.M. Bustillo, R.T. Howe, R.S. Muller, Surface micromachining for 
microelectromechanical systems, Proceedings of the IEEE 86(8) (1998) 1552-1574. 
[20] G.T. Kovacs, N.I. Maluf, K.E. Petersen, Bulk micromachining of silicon, 
Proceedings of the IEEE 86(8) (1998) 1536-1551. 
[21] A.R. Grayson, R.S. Shawgo, A.M. Johnson, N.T. Flynn, Y. Li, M.J. Cima, R. 
Langer, A BioMEMS review: MEMS technology for physiologically integrated 
devices, Proceedings of the IEEE 92(1) (2004) 6-21. 
85 
 
[22] D.L. Polla, A.G. Erdman, W.P. Robbins, D.T. Markus, J. Diaz-Diaz, R. Rizq, 
Y. Nam, H.T. Brickner, A. Wang, P. Krulevitch, Microdevices in medicine, Annual 
review of biomedical engineering 2(1) (2000) 551-576. 
[23] K. Ita, Reflections on the Insertion and Fracture Forces of Microneedles, 
Current drug delivery 14(3) (2017) 357-363. 
[24] S.P. Davis, B.J. Landis, Z.H. Adams, M.G. Allen, M.R. Prausnitz, Insertion of 
microneedles into skin: measurement and prediction of insertion force and needle 
fracture force, Journal of biomechanics 37(8) (2004) 1155-1163. 
[25] T. Baldacchini, Three-dimensional Microfabrication Using Two-photon 
Polymerization: Fundamentals, Technology, and Applications, William 
Andrew2015. 
[26] C.N. LaFratta, J.T. Fourkas, T. Baldacchini, R.A. Farrer, Multiphoton 
fabrication, Angewandte Chemie International Edition 46(33) (2007) 6238-6258. 
[27] K.-S. Lee, R.H. Kim, D.-Y. Yang, S.H. Park, Advances in 3D 
nano/microfabrication using two-photon initiated polymerization, Progress in 
Polymer Science 33(6) (2008) 631-681. 
[28] L. Li, J.T. Fourkas, Multiphoton polymerization, Materials Today 10(6) 
(2007) 30-37. 
[29] M. Malinauskas, M. Farsari, A. Piskarskas, S. Juodkazis, Ultrafast laser 
nanostructuring of photopolymers: A decade of advances, Physics Reports 533(1) 
(2013) 1-31. 
[30] H.-B. Sun, S. Kawata, Two-photon photopolymerization and 3D lithographic 
microfabrication, Advances in Polymer Science 170 (2004) 169-274. 
[31] S. Maruo, O. Nakamura, S. Kawata, Three-dimensional microfabrication with 
two-photon-absorbed photopolymerization, Optics letters 22(2) (1997) 132-134. 
[32] S. Wu, J. Serbin, M. Gu, Two-photon polymerisation for three-dimensional 
micro-fabrication, Journal of Photochemistry and Photobiology A: Chemistry 
181(1) (2006) 1-11. 
86 
 
[33] A. Selimis, V. Mironov, M. Farsari, Direct laser writing: Principles and 
materials for scaffold 3D printing, Microelectronic Engineering 132 (2015) 83-89. 
[34] T.Y. Huang, M.S. Sakar, A. Mao, A.J. Petruska, F. Qiu, X.B. Chen, S. 
Kennedy, D. Mooney, B.J. Nelson, 3D printed microtransporters: compound 
micromachines for spatiotemporally controlled delivery of therapeutic agents, 
Advanced Materials 27(42) (2015) 6644-6650. 
[35] C. Peters, M. Hoop, S. Pané, B.J. Nelson, C. Hierold, Degradable magnetic 
composites for minimally invasive interventions: Device fabrication, targeted drug 
delivery, and cytotoxicity tests, Advanced Materials 28(3) (2016) 533-538. 
[36] A. Otuka, D. Corrêa, C.R. Fontana, C.R. Mendonça, Direct laser writing by 
two-photon polymerization as a tool for developing microenvironments for 
evaluation of bacterial growth, Materials Science and Engineering: C 35 (2014) 
185-189. 
[37] P. Danilevicius, S. Rekstyte, E. Balciunas, A. Kraniauskas, R. Jarasiene, R. 
Sirmenis, D. Baltriukiene, V. Bukelskiene, R. Gadonas, M. Malinauskas, Micro-
structured polymer scaffolds fabricated by direct laser writing for tissue 
engineering, Journal of biomedical optics 17(8) (2012) 0814051-0814057. 
[38] J. Torgersen, A. Ovsianikov, V. Mironov, N. Pucher, X. Qin, Z. Li, K. Cicha, 
T. Machacek, R. Liska, V. Jantsch, Photo-sensitive hydrogels for three-dimensional 
laser microfabrication in the presence of whole organisms, Journal of biomedical 
optics 17(10) (2012) 105008-105008. 
[39] M.T. Raimondi, S.M. Eaton, M.M. Nava, M. Laganà, G. Cerullo, R. Osellame, 
Two-photon laser polymerization: from fundamentals to biomedical application in 
tissue engineering and regenerative medicine, J Appl Biomater Biomech 10(1) 
(2012) 55-65. 
[40] T. Gissibl, S. Thiele, A. Herkommer, H. Giessen, Two-photon direct laser 
writing of ultracompact multi-lens objectives, Nature Photonics 10(8) (2016) 554-
560. 
87 
 
[41] A. Žukauskas, M. Malinauskas, C. Reinhardt, B.N. Chichkov, R. Gadonas, 
Closely packed hexagonal conical microlens array fabricated by direct laser 
photopolymerization, Applied optics 51(21) (2012) 4995-5003. 
[42] V. Chernow, H. Alaeian, J. Dionne, J. Greer, Polymer lattices as mechanically 
tunable 3-dimensional photonic crystals operating in the infrared, Applied Physics 
Letters 107(10) (2015) 101905. 
[43] J.K. Gansel, M. Thiel, M.S. Rill, M. Decker, K. Bade, V. Saile, G. von 
Freymann, S. Linden, M. Wegener, Gold helix photonic metamaterial as broadband 
circular polarizer, Science 325(5947) (2009) 1513-1515. 
[44] M. Offenberg, Process for producing surface micromechanical structures, 
Google Patents, 1997. 
[45] K. Murakami, Y. Wakabayashi, K. Minami, M. Esashi, Cryogenic dry etching 
for high aspect ratio microstructures, Micro Electro Mechanical Systems, 1993, 
MEMS'93, Proceedings An Investigation of Micro Structures, Sensors, Actuators, 
Machines and Systems. IEEE., IEEE, 1993, pp. 65-70. 
[46] M.J. De Boer, J.G. Gardeniers, H.V. Jansen, E. Smulders, M.-J. Gilde, G. 
Roelofs, J.N. Sasserath, M. Elwenspoek, Guidelines for etching silicon MEMS 
structures using fluorine high-density plasmas at cryogenic temperatures, Journal 
of microelectromechanical systems 11(4) (2002) 385-401. 
[47] J. Ji, F.E. Tay, J. Miao, J. Sun, Characterization of silicon isotropic etch by 
inductively coupled plasma etcher for microneedle array fabrication, Journal of 
Physics: Conference Series, IOP Publishing, 2006, p. 1137. 
[48] S. McAuley, H. Ashraf, L. Atabo, A. Chambers, S. Hall, J. Hopkins, G. 
Nicholls, Silicon micromachining using a high-density plasma source, Journal of 
physics d: applied physics 34(18) (2001) 2769. 
 
 
 
88 
 
Chapter III 
 
Results and Discussion 
 
The main aim of this thesis was to produce polymeric microneedles embedding 
model drugs for dermal drug delivery. The method used in this work overcomes the 
limitations related to the known methods, in particular those related to the micro-
casting and drawing lithography, since heating, multi-step processes and hazardous 
UV are not required.[1, 2] This study presents an approach for the realization of 
double-compartment microneedles for the delivery of two model drugs in 
sequence. In particular, one is a PVP compartment as a fast dissolvable matrix 
which was loaded with FITC and another compartment, based on porous PLGA 
microspheres assembled each other, which was loaded with Sulforhodamine B used 
to simulate the possible cargo. To fabricate the polymer microneedles needed to 
achieve these design goals, we employed a molding technique using (PDMS) 
molds. PDMS molds have been produced by replica molding from masters 
produced with different microfabrication techniques, such mold being provided 
with an array of cavities having the shape of a microneedle. Such microneedles 
have then been harvested from the mold by means of a water-soluble polymeric 
layer, morphological analysis was conducted and indentation tests in vitro have 
been carried out, to demonstrate the mechanical properties of microneedles 
product. 
3.1 Microspheres production 
Polymeric microspheres have been employed as starting material for the production 
of biodegradable polymeric microneedles. Such microspheres have been produced 
by means of a double emulsion process. 
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The choice of materials for the microparticles must satisfy multiple criteria that 
vary depending on the patch design and among the patch components. The 
microspheres were made of PLGA and Sulphorhodamine B, as a model drug. 
PLGA was selected since it is a very well-known biodegradable material, which is 
FDA approved, and has suitable mechanical properties for the production of 
microneedles for drug delivery.[3] In particular, a T 25 digital ULTRA-
TURRAX® was used for the double emulsion according to the procedure reported 
in the Materials and Methods section, to produce porous microspheres in the range 
of 1-15 μm. The choice of  using a double emulsion for microparticles is due to the 
possibility to use different cargos such as a hydrophobic one in the matrix of 
microparticles and a hydrophilic one in the pores of the microparticles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1. a) SEM image of Porous Microspheres; b)Volumetrical analysis of microparticles with 
Mastersize. 
 
 
a) 
b) 
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3.2 PVP production 
Drug is typically present in a water-soluble matrix that dissolves in the skin. This 
matrix must be not only biocompatible, but also suitable for delivery into and 
clearance from the body. This usually means, at a minimum, the matrix must be on 
the FDA's Generally Regarded As Safe list and, more ideally, has been safely used 
in parenteral (i.e., injectable) products. It also should be water-soluble and, when 
rapid onset of drug delivery is desirable, exhibit rapid dissolution in the skin. The 
material should also be compatible with the drug it encapsulates during 
manufacturing, storage, and delivery. 
When this matrix is used as a coating on microneedles, it must form films on the 
microneedles that remain adherent during storage and skin insertion and should be 
amendable to coating processes. When this matrix forms the microneedle (i.e., 
dissolving microneedles), then it must also satisfy the mechanical strength 
requirement to make a strong microneedle. In this study, PVP was chosen as the 
structural material for the fabrication of the tips of microneedles , in an aqueous 
environment at room temperature. As it is well known, organic solvents and 
elevated temperatures may denature the activity of encapsulated drugs, this choice 
is also good for the encapsalution of thermolabile drugs. PVP is mechanically 
strong as MNs because of its chemical backbone that contains rigid rings. 
Additionally, PVP is water soluble, facilitating a rapid dissolution of MN arrays 
when inserted into skin. Once dissolved in the body, PVP can be safely excreted 
through the glomerulus within a few days [4]. The PVP used in this work is PVP at 
55 kD. It was dissolved in 1 ml of water at a concentration of 25% w/v, with the 
addition of 0.5µl of FITC .200 µl of PVP at 25% was used to produce tip of 
microneedles . 
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3.3 Mold production 
In order to prepare the microneedles, PDMS stamps, replicated onto masters made 
of different materials and techniques, were employed. The mold used to produce 
microneedles has conical shape and pyramid tip-shaped cylinders of different sizes, 
the first was entirely produced with a 2 Photon Laser, the second was produced by 
sequential combination of 2D Laser and ICP RIE techniques. With the first 
technique, the master was made of the negative photoresist IP-DIP, while with the 
second technique, the master was made of silicon. The first technique provided a 
master with high resolution, tunable different sizes and shapes. On the other hand, 
the photoresist can detach from the substrate after some uses; moreover, the serial 
production is very slow with a basic setup (piezo mode) but can be made faster 
with the new up-grade (galvo stage). In order to enhance the adhesion of the 
photoresist to the glass substrate, this was first treated with a plasma O2 and then it 
was covered with the photoresist by the spin-coating technique, then was cured 
with UV lamp for 3 h. The cured photoresist was coated with another layer of 
uncured photoresist that is the ultimate layer exposed to the 2 Photon Laser. The 
microneedles layout was designed with selected conical hollows in order to reduce 
the production time. 
With the second technique it was possible to obtain a master with excellent 
micromechanical properties and the process was quite fast after fine tuning of the 
process parameters. In this case, only limited dimensions and geometries can be 
realized and each time a long optimization procedure of the etching parameters 
during the ICP-RIE step is needed.  
The dimension of the cone produced by 2 Photon Laser was 150 or 300 µm of base 
diameter and 300 or 600 µm of height, while the array of microneedles is extended 
onto an area of 1 cm
2
. Microneedles are assembled into arrays that typically range 
from tens to tens of thousands of microneedles. Array area is often in the 1–10-cm2 
range. This can result in a wide range of microneedle densities. A large 
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microneedle density (i.e., requiring thinner and therefore shorter microneedles) can 
suffer from the ―bed-of-nails‖ effect, where the insertion force is distributed among 
too many microneedles so that none penetrate the skin. This may be overcome by 
having sharper tips and stronger insertion forces.[5-7] Smaller microneedle density 
makes skin insertion easier and accommodates wider and therefore longer 
microneedles, but the smaller number of microneedles typically reduces the amount 
of drug that can be delivered. Increasing microneedle array area accommodates 
more microneedles but can increase pain.[8, 9] 
The microneedles obtained by 2D laser and ICP-RIE have a pyramidal tip standing 
onto a cylindrical structure. In particular, the process was optimized to obtain a 
pyramidal tip with 60 µm of height and 112 µm of base diameter onto a cylindrical 
pillar with 150 µm of height and the same base diameter of the pyramidal structure.  
 
 
 
 
 
Fig. 3.2. a) Optical images of array of microneedles of 300 µm height and 150 µm diameter of base 
scale bar 600 µm; b) Array Microneedles of 600 µm height and 300 µm diameter of base scale bar 
1.2 mm. 
  
 
a) 
b) 
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Fig. 3.3. SEM images of maicroneedles (scale bar 150 µm) (a) and array of microneedles (scale bar 
600µm) (b) produced by 2D laser and ICP-RIE. 
 
PDMS was used for the fabrication of the stamp. As previously described, PDMS 
prepolymer was mixed with the curing agent at the ratio of 10:1 and degassed 
under vacuum until complete disappearance of the air bubbles. Then, the PDMS 
was poured on the master, cured at 70 °C for 1 h and finally peeled off from the 
master. Fig. 3.3 shows the PDMS mold. 
 
 
 
                   a) 
 
 
 
 
                          b) 
 
Fig. 3.4. Stereomicroscope images of PDMS mold used for microneedles fabrication taken after 
sectioning: a) conical shape (scale bar 600 µm) and b) cylinder with pyramidal tip (scale bar 300 
µm). 
a) 
 
b) 
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Fig.3.5. Optical microscope of the PDMS stamp with cone shape. 
3.4 Production of microneedles 
Polymer microneedles can be made using various methods most commonly 
involving casting liquid solutions onto an inverse mold of the MNP that is often 
made of polydimethyl siloxane to make dissolving microneedles, hydrogel 
microneedles, and, in some cases, coated microneedles.[10] After drying, the MNP 
is peeled out from the mold. MNPs made in this way have been studied for 
influenza vaccination in clinical trials.[11, 12] Two-photon polymerization has also 
been used to make polymer microneedles.[13] Casting solvent onto molds, where 
the solvent typically is water, is often used to make polymer microneedles.[10, 14] 
In some cases, two different formulations are casted sequentially onto the molds. 
The first cast contains the drug, in addition to other excipients, and is used to fill 
the mold cavities forming the microneedles. The second cast contains no drug and 
is used to fill any remaining space in the mold cavities and to form a film on the 
surface of the mold to create the MNP base substrate. In this way, drug is located 
only in the microneedles and not in the base substrate.  
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To make the microneedles, the formulation needs to meet certain requirements: it 
must be compatible with the drug, fillable into the mold cavities (e.g., sufficiently 
low viscosity, often with the aid of vacuum), and mechanically strong. To dissolve 
microneedles, it also needs to exhibit (rapid) dissolution in the skin. The 
formulation used to make the base substrate may need to have less drug solubility 
if the base substrate is designed to contain no drug. It could also have higher 
viscosity and be mechanically weaker after drying (and in some cases designed to 
be flexible). In addition, it may not need to be water-soluble. 
After casting, the MNP needs to be dried before removal from the mold, assembled 
into a patch, and placed in packaging. When double casting is used, the first cast is 
often at least partially dried before the second cast is applied. Rapid drying is 
desirable (e.g., using heat and/or vacuum), but loss of drug activity (especially for 
biological molecules and vaccines) is often associated with drying, so drying 
conditions must be optimized to maintain drug stability.[15-17] Air drying is 
typical, but lyophilization has also been used.[17] With different techniques it is 
possible to obtain only a fast release of drug, after indentation in the skin. In this 
work I developed two approaches in parallel. In both cases, the aim was to develop 
microneedles able to combine bolus and long-term dosing of cargos released from 
cutaneous implanted PVP and PLGA depots, respectively. 
 
First Procedure 
The microspheres were placed inside the cavities of the mold under a 
stereomicroscope as shown in fig. 3.6.  
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Fig. 3.6. Optical microscope of microspheres in the cavities of the mold scale bar 600 µm. 
After filling up the mold with the microspheres, they were exposed to a vapor 
mixture of solvent non solvent in order to carry out a novel and mild plasticization 
able to assemble the microparticles in the shape of microneedles while keeping the 
microstructure of the starting microparticles. 
This mild softening method was developed in a previous work for the mild 
deformation of single microparticles located in the cavities of a PDMS stamp.[5] In 
this work of thesis this patented method has been applied to multiple microparticles 
in order to promote their assembly by gentle sintering in the cavities of the stamp. 
In this way it has been possible to better reproduce more complex structures like 
microneedles with high aspect ratio with no need to use strong plasticization on 
single microparticles.[18] The advantage of inserting multiple microparticles 
consists on the formation of a sharper tip of the microneedles employing mild 
plasticization conditions that do not impair the internal structure and do not alter 
the properties of the encapsulated drug. The microneedles produced with the 
previous method are separated from each other; it‘s possible to extract single 
microneedles by the mold as possible to see in the figure 3.7.   
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Fig. 3.7. Stereomicroscope images of (a) conical microneedles extracted from the mold and (b) 
array of cylindrical microneedles. 
 
 
The as-produced microneedles show a tip with radius of curvature larger than 
corresponding mold. To overcame this limit, it has been used a hydrophilic matrix 
deposited on the mold cavities after the first step. The hydrophilic matrix was 
composed of PVP at 25% w/v in water. PVP was selected since it is biodegradable 
and biocompatible approved by FDA administration. Fig. 3.8 shown array of 
microneedles product with this process. 
a) b) 
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Fig. 3.8. a) SEM image of an array of cylindrical microneedles with pyramidal tip produced with 
the first process, and b) Stereomicroscope image of an array of conical microneedles produced with 
the first process. 
Second procedure 
Another procedure which is able to provide sharp tips has been developed during 
the work.  
In this second procedure we started from a hydrophilic polymer solution with PVP 
at 25% (w/v), embedding a model drug, to produce the tip, by filling the cavities of 
the stamp, degassing and carrying out a spin coating to spread out the excess of 
solution from the stamp and allow a fast evaporation of the residual solvent. 
a) 
b) 
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Fig. 3.9. Production process of microneedles tip. a) Deposition of PVP with Gilson on the PDMS 
mold; b) Degassing process of solution with PUMP; c) spin coating technique to produce only PVP 
microneedles. 
 
After filling with PVP the apical part of the cavities, next steps were the same. 
Stamp cavities were filled with the same microparticles in the range of 1-15 µm 
under microscope, as shown in fig. 3.4.  
Then, it followed the same plasticization step by exposing microparticles to the 
vapor of solvent-non solvent mixture and the evaporation of the solvent. Then, it 
followed the same step of consolidation based on the evaporation of the liquid 
phase based on the solvent-non solvent mixture. To extract microneedles, it was 
used also in this case a 3M Medical tape but first a droplet of PVP solution was 
deposited on medical tape to promote more adhesion from the microneedles array 
and medical tape, as shown in fig. 3.10. 
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Fig.3.10. a) PVP droplets on the medical tape b) 3M Medical tape. 
 
The microneedles obtained with this second procedure presented a different 
distribution of the two compartments of the microneedles since the fast dissolvable 
is localized in the tip. 
 
Fig. 3.11. a) Stereomicroscope image of microneedles array b) SEM Image microneedles array. 
The most similar procedure reported so far is the one published by Irvine and his 
group, who manufactured arrays of microneedles composed of drug-loaded PLGA 
microparticles with a supporting and rapidly water-soluble PAA matrix.[19] In that 
work PLGA microparticles always obtained by double-emulsion-solvent-
evaporation were applied to the surface of the mold in aqueous suspension and 
compacted into the mold cavities through centrifugation. Excess microparticles 
were then removed from the PDMS surface and the microparticle-loaded mold was 
allowed to dry. To form dissolving microneedles carrying dispersible PLGA 
microparticles, they next added a concentrated aqueous solution of PAA (35 wt%) 
a) b) 
a) b) 
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to the mold surface and infiltrated the PAA solution into the packed PLGA particle 
bed via centrifugation. The loaded molds were then dried at 25°C for 48 h before 
desiccation under vacuum to obtain solid PLGA-PAA microparticle matrices. The 
dry composite microneedles were finally removed from the PDMS mold. 
That procedure is quite long and can lead to the loss of part of the hydrophilic drug 
from the microparticles which are dispersed in water during the process. 
Additionally, the centrifugation cannot guarantee a fine control over the 
homogeneous filling of mold cavities.  
 
Fig.3.12. SEM images of (a) microparticles-encapsulating microneedle array (scale bar 200 μm)[19] 
and (b) of microneedles produced with the proposed protocol.   
 
The MA microneedles proved thermostable and able to perforate the stratum 
corneum and implant the antigen/adjuvant-loaded PLGA microparticles in the 
epidermal compartment following patch removal due to rapid separation of 
microneedles from PVP layer used for the microneedles extraction.  
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3.5 Porosity analysis 
The morphological analysis of microneedles was performed with a Scanning 
Electron Microscope (SEM), to understand if the process used for the production of 
microneedles could modified the morphology of the microspheres. For this reason, 
microneedles and microspheres were incorporated in PDMS, cured for 24 h at 
room temperature, and then frozen at -130 °C in Leica Cryo Ultra Microtome EM-
FC7-UC7. Samples were sectioned at a thickness of 5 µm for analysis in axial 
direction.  
Microneedles porosity is of fundamental importance for the drug release kinetics. 
Samples were sputter coated with a 15 nm thick gold layer and to avoid damage 
inside them, it was imposed a voltage (EHT) limited to 10-20 kV.  
Morphological analysis of porosity was carried out both on microneedles and on 
microspheres. 
 
 
Fig. 3.13. SEM image of microspheres slice. 
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Fig 3.14. Representative SEM images of a) embedded PLGA microparticles and b) slice of 
microneedles product.  
 
In both slices similar porosity can be observed, demonstrating that the treatment to 
which the microspheres are subjected for the production of microneedles do not 
involve any change in the morphological structure of microspheres. This is one of 
the most important aspects that this work demonstrated because in this way it is 
possible to exploit and apply the knowledge on the kinetic release of the cargo 
encapsulated in the PLGA microparticles to this novel device based on 
microneedles. Additionally, it is possible to combine a fast release from the fast 
dissolvable polymer matrix. 
3.6 Hydrophilic drug loading 
Two different hydrophilic chromophores have been used, to conduct the analysis of 
drug loading. Fitc used in the polymeric matrix, and Sulphorodamine B used in the 
pores of the microparticles. Confocal analysis was used to characterize both 
microneedles obtained with the two different procedures. Fig. 3.14 is referred to 
microneedles obtained with the first procedure. In fig. 3.14a it is depicted a 
microneedle extracted with no polymer matrix surrounding microparticles and 
despite the absence of such matrix microparticles are assembled each other and at 
the same time it is still possible to appreciate their individuality with their spherical 
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shape. In the fig. 3.14b it is reported a slice of such microneedles where the 
individuality of the microparticles is also evident inside the microneedle.  
In fig. 3.14c it is depicted a microneedle with PVP matrix where it is possible to 
see the green color around microparticles. This is even more evident from fig 3.14d 
representing a slice of such microneedle. Green color is homogeneously distributed 
around the microparticles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.15. Confocal analysis of a) microneedles obtained by microparticles sintering, b) a slice of 
microneedle obtained by microparticles sintering, c) microneedle obtained by microparticles 
sintering and hydrophilic matrix, d) slice of microneedle obtained by microparticles sintering and 
hydrophilic matrix. 
 
 
a) c) 
b) d) 
105 
 
Confocal analysis was also performed on microneedles obtained with the second 
procedure. In the mean time we optimized a reconstruction procedure that we used 
for the representation of the confocal results on the microneedles obtained with the 
second procedure. This is a reconstruction of z slice images which can be 
performed with LAS X software used for 3D reconstruction imaging. From the 
reconstructed image (fig. 3.15 and 3.16) it is clear that the fast dissolvable 
compartment made of PVP loaded with Fitc is located in the tip of the microneedle 
as expected from the process. Indeed, in this case the solution of PVP is dispensed 
in the cavities of the stamp before the insertion of the microparticles.   
 
     
                     
 
 
  
  
Fig. 3.16. 3D Confocal reconstruction of a microneedles array.   
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Fig. 3.17. 3D Confocal reconstruction of single compartments forming microneedles (a,b) and their 
matching (c). 
3.7 Indentation tests 
The fundamental requirement of the microneedles is that they are able to pierce the 
stratum corneum of the skin. For this reason, different indentation tests were 
carried out in this thesis. 
3.7.1 Preliminary test 
The first indentation test was performed in a photo-curable gelatin which is the 
simplest model of derma with the aim to check if thanks to the fast dissolvable base 
of the microneedles it was possible to release microneedles in the skin model. The 
gelatin used for this test was gelatin B with DS 64%. Briefly, 200 mg of gelatin and 
2 ml of solution, in the ratio 10:1 were mixed and consolidated as described in the 
Materials and Methods section  
Then the indentation tests were carried out by pressing the array of microneedles in 
the gelatin and after 1 h the array was removed. The microneedles stayed inside the 
gelatin showing the ability of our microneedles array to be released and therefore 
implanted upon indentation thanks to the fast dissolvable layer at the base of the 
microneedles themselves. 
 
a b c 
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Fig. 3.18. Stereomicroscope image of microneedles in the gelatin. 
 
The second indentation test was performed in a layer of paraffin wax prepared as 
described in Materials and Methods section. Paraffin is a more appropriate model if 
the aim is to assess the mechanical resistance of the microneedles and therefore 
their capability to survive to the applied pressure and promote the indentation. It is 
a fast model for a fast testing. 
The indentation test was carried out by pressing the array of microneedles in the 
paraffin wax and after 15 min the array was removed. 
To monitor the effective indentation of microneedles in the paraffin wax, a replica 
onto the paraffin wax with PDMS was carried out. The PDMS after 24 h was 
detached from the paraffin wax and it was observed at the SEM. Fig. 3.19, shows 
the replica of the indentations carried out with microneedles in the paraffin it is 
possible to clearly see the perfect replica of the microneedles used and the high 
resolution of the tip obtained.  
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Fig 3.19. Stereomicroscope image of replica whit PDMS of paraffin wax 
 
3.7.2 Skin indentation 
Finally, indentation experiments were performed into real skin. 
This analysis was carried out using the applicator system showed in Fig. 2.13. This 
applicator is suggested to perform reproducible indentations. 
Pig cadaver skin was kept on an absorbing paper and microneedles were inserted 
into the skin and removed after 5 min. 
The effectiveness of the indentation was confirmed by the cross sectional image of 
the stained skin at the site of microneedle penetration (fig. 3.20). 
            
 
         
Fig. 3.20. Cross-sectional image of the skin after microneedle removal and skin fixing in formalin at 
10% v/v. 
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The effectiveness of the indentation was confirmed also by the optical image, 
reported in fig.3.21, showing microneedles staying in the skin after indentation test 
and removal of the medical tape.  
 
  
Fig. 3.21 Stereomicroscope image of microneedles into the skin. 
 
The dermis was clearly reached by the microneedles, thus confirming the potential 
use for drug delivery. In particular, they were able to penetrate all the layers of the 
epithelium and part of the papillary dermis.  
 
Moreover, the indentation was confirmed by the analysis of the cleared skin using a 
multiphoton microscope. Confocal images in Fig. 3.22 clearly show the formation 
of holes in the indented skin, visible thanks to the insertion of Sulforodhamine B 
into the microneedle tip that is released after skin indentation. 
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Fig. 3.22. Multiphoton image of indented skin (a and b), (c) 3D reconstruction of the holes.   
Overall these results confirmed the effectiveness of the so obtained microneedles. 
The good indentation properties joined with the technological simplicity of the 
fabrication process might provide a significant breakthrough in the clinical 
development of the biodegradable microneedles. 
3.8 Conclusions  
Microneedles and in particular polymeric microneedles in the last years have been 
described as a great alternative to the traditional drug delivery systems. They have 
been mainly tested with different drugs and vaccines, and the main advantage is the 
possibility to encapsulate and deliver through the skin high molecular weight 
molecules being the tool able to indent and cross the stratum corneum. Main 
limitation is on the fabrication procedures which are typically time consuming and 
A B 
C 
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therefore expensive. Additionally, there is still much room to improve the product 
by itself by improving the procedure and therefore the final performances of the 
product in terms of fine control of the release of both hydrophilic and lipophilic 
molecules. 
Therefore, in this thesis, main focus was on the development of a novel procedures 
for the fabrication of microneedles remaining in the field of stamp based 
techniques. Additionally, the design of the procedure was such that we could also 
provide high performing microneedles and in this respect we produced 
biodegradable and multi-compartment microneedles with two different degradation 
times so to combine fast and prolonged release. This work started with the 
optimization of the processes to produce masters which are needed for the 
realization of stamps by replica. We developed two procedures which are both fast 
and carried out at room temperature to preserve thermolabile drugs, such as 
proteins. Depending on the procedure it is possible to change the distribution of the 
two compartments. For instance, in the second case the fast dissolvable 
compartment is localized in the tip of the microneedles while in the first procedure 
is homogeneously distributed all over the volume of the microneedle. In this way it 
is possible to confirm that the drug is encapsulated in the microneedles, so as to 
reduce the loss of medication. 
Being stamp based procedures it is possible to obtain different shapes of 
microneedles which may be studied in future in terms of final performances.  
The microneedles realized were separated each other which allow integration on 
flexible patches to improve the conformal contact with the skin. The multi-
compartment feature allows a temporal and spatial control of the molecule to be 
released.  
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CHAPTER IV 
 
Microneedles for cosmeceutical applications 
 
4.1 Introduction 
Cosmeceuticals represent the future generation of skin care. They are based on the 
advances made within the world of dermatological products and the new backbone 
in skincare. Cosmeceuticals are typically cosmetic-pharmaceutical hybrids intended 
to enhance the health and beauty of skin. Some cosmeceuticals are naturally-
derived while others are synthetic, but all contain functional ingredients with either 
therapeutic, disease-fighting or healing properties. 
These are skin-care products that go beyond coloring and adorning the skin. In the 
last years, skin-lightening agents added to product formulations have become 
increasingly popular and such products are in demand.  
4.1.1 Skin whitening 
Skin whitening is the practice of using substances, mixtures, or physical treatments 
to lighten skin color. Skin whitening treatments work by reducing the content 
of melanin of the skin. Many agents have been shown to be effective in skin 
whitening; some have beneficial side effects (e.g.: are antioxidants,[1] nutrients, or 
decrease the risk of some types of cancer); some are of significant risk to health 
(for example, those containing mercury). Specific zones of abnormally high 
pigmentation such as lentigo spots, moles and birthmarks may be depigmented to 
match to the surrounding skin.  
Cosmetics preparations for skin whitening are available in cream, soap, lotion, 
nasal spray and injectable form. When applied on the skin in the form of lotion the 
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product is not efficiently absorbed by the skin. When taken orally, it is hydrolyzed 
by enzymes in the gastrointestinal tract resulting in reduced bioavailability. On the 
contrary, intravenous administration delivers very high doses directly into the 
systemic circulation and is the preferred route. However, this method of 
administrating the antioxidant might flood the cells that may cause reductive 
stresses. 
Both ablative and non-ablative lasers can have a profound effect on melasma. 
However, the results are not always consistent, and problems have been reported 
(such as hypo- or hyperpigmentation). Laser treatments of this kind are more likely 
to result in problems for those with darker skin tones.[2] 
Another alternative to laser treatment is cryosurgery using liquid nitrogen. 
Controlled destruction of skin cells causes the skin to naturally regenerate itself. 
Excess melanin comes to the surface and peels off in a few days. This is 
particularly useful in sensitive areas like the genitals where laser treatment could 
leave a scar. Efficacy of the treatment depends on the depth of the pigment.  
More recently, however, the use of MN in the cosmeceutical industry has been 
explored.  
Two commercially available MN devices, namely Dermaroller
®
 and Dermapen
®
, 
were developed based on these principles and Fernandes‘ percutaneous collagen 
induction (PCI) innovation.  
PCI is achieved via multiple needle application.[3, 4] Roller devices with 
projecting needles have been designed to achieve this aim. The Food and Drug 
Administration (FDA)-approved Dermaroller
® 
is described as a hand-held device 
equipped with medical grade solid steel MNs, projecting from a cylindrical roller 
fig. 4.1.a.[5] The rolling mechanism is applied directly over the skin, vertically, 
horizontally and diagonally. There are 24 circular arrays of eight needles each 
located on the roller (total 192 needles).[4] Fig. 4.1a, and the heights of the needles 
are specific to the nature of the treatment being employed.[6] Home 
Dermarollers
®
 consist of the Home Roller C 8 (a single needle which is depicted in 
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Fig. 3b) and the Beauty Mouse
®
. The cosmetic C 8 is the name of model has 
needles ranging between 130 and 200 μm in height (Fig. 4.1b), with a penetration 
diameter of 70 μm. Another device intended for home use is the Beauty Mouse®, 
which incorporates 3 Dermarollers
®
 with a total of 480 needles and has been 
developed to ensure coverage of larger skin surface areas, such as the arms, legs 
and buttocks for the treatment of stomach or thigh stretch marks and cellulite.[7] 
A number of other companies, for example, Hansderma and White Lotus, have 
marketed products with similar functions.[8, 9] Despite the fact that MN devices 
are often categorized into home and medical use in product literature, they are 
available for purchase by any individual online from a multitude of commercial 
websites. With no restriction on purchasing of these products, it is clearly evident 
that there is potential for abuse and misuse of these devices. 
 
Fig. 4.1. FDA-approved MN devices. a) Image of a Dermaroller
®
 MF 8 (35; (b, c and d) stereo 
microscopic images (Leica MZ 8, Switzerland) of the needles from different Dermaroller
®
 models, 
namely b) cosmetic Dermaroller
®
 C 8 model, medical models, c) Dermaroller
®
CIT 8 and d) 
Dermaroller
®
MF 8, scale = 500 μm.[4] e) Images of the MDerma FDS which will be ready for 
distribution in early 2015 (Images taken from a marketing PDF received from Dermapen
®
). f) An 
image of LED MicroNeedling Rollers. 
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PCI technology has subsequently evolved with the emergence of miniature 
versions of the Dermaroller
®
, termed Dermastamps
™
 onto the UK market.[10] 
These are sterile medical devices with needle heights of 200 μm, situated in a 5 mm 
diameter circular arrangement.[10] They are specifically designed to accommodate 
small confined areas where it is difficult for the Dermaroller
®
 to achieve optimal 
stimulation, for example the upper lip. The device uses ‗vertical penetration to 
create infusion channels‘ in the skin and is considered ideal for use on isolated 
scars and wrinkles.[10] 
Designed to overcome the issues of varying pressure application by 
physicians/users and the subsequent MN depth penetration achieved, an advanced 
microneedling device has been launched, termed the Dermapen
®
 (Fig. 4.1 e). It is 
described by manufacturers as a spring-loaded, fractional MN device, with an 
adjustment ring allowing for alteration of the heights of the MN, which carries out 
the function of ‗fractional mechanical resurfacing‘. It utilizes an electrically 
powered pen to deliver a vibrating stamp-like motion to the skin, creating a series 
of micro-channels in it. Treatments in acne scarring and photoageing are being 
investigated by the manufacturers, although no research studies focusing on this 
MN device have yet been published. Due to the substantial interest in these MN 
devices, more commercial products based on the same principles are currently 
under development.[6, 7, 11]  
One of the most important advantages of these MN devices is in overcoming the 
use of traditional ablative methodologies. Ablative methods including 
dermabrasion, chemical peels, collagen injections, cortisone-like injections, 
cryosurgery and laser resurfacing are, by their nature, extremely physically 
disruptive to the targeted epidermis and superficial dermis.[12] In ablative 
methodologies such as these, undesired post-operative changes in the skin can 
result in significant healing times. As destruction, rather than disruption, of the 
epidermis initiates an inflammatory response that stimulates fibroblasts to produce 
thick branches of scar collagen,[13] skin has been shown to become more sensitive 
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to photodamage and one study has stated that a side effect of such treatment may 
be the development of dyschromias, a common skin disorder whereby there is a 
marked alteration in normal skin pigmentation, resulting in discolouration of the 
skin, hair and nails.[14] In contrast, microneedling, if limited to breacking 
the SC with needles of appropriate heights, would avoid the risks and negative side 
effects often observed with invasive ablative approaches. The main limit of this 
technique is related to the fast closure of the skin holes that prevents an effective 
injection of functional high molecular weight compounds.  
In this scenario is set the present work aimed at the realization of biodegradable 
multi-compartment polymeric microneedles for cosmetic applications in particular 
for skin lightening application.  
4.1.2 Laccase 
Laccase is one of the few enzymes that have been the subject of study. In 1883, 
laccase was first described by Yoshida when he extracted it from the exudates of 
the Japanese lacquer tree, Rhus vernicifera.[15] Their characteristic as a metal 
containing oxidase was discovered.[16] In 1896, both Bertrand and Laborde 
observed the presence of laccase in fungi for the first time.[17] Laccase has 
received lot of attention from researchers due to its ability to degrade a variety of 
recalcitrant pollutants. Compounds which are structurally similar to lignin can be 
oxidized [18] by fungal laccase (benzene diol: oxygen oxidoreductase, EC 
1.10.3.2) along with ferroxidases (EC 1.16.3.1). Multicopper oxidases (MCO) 
typically contain two or four copper atoms per protein molecule and they catalyze 
oxidation reactions. In these reactions, electrons are removed from the reducing 
substrate molecules and transferred to oxygen in order to form water without the 
step of hydrogen peroxide formation.[19] Laccases have a wide substrate range, 
which can serve industrial purposes. The simple requirements of laccase catalysis 
(presence of substrate and O2), as well as its apparent stability and lack of 
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inhibition (as has been observed with H2O2 for peroxidase), make this enzyme both 
suitable and attractive for industrial applications. In addition, laccase can oxidize a 
wide range of organic and inorganic substrates, including mono, di, polyphenols, 
aminophenols, methoxyphenols as well as metal complexes which are the major 
reason for their attractiveness for dozens of biotechnological applications. 
 
Fig.4.2. Application of laccase in biotechnology 
4.1.3 Medical and personal care application 
Many products generated by laccases are antimicrobial, detoxifying, or active 
personal-care agents. Due to their specificity and bio-based nature, potential 
applications of laccases in the field are attracting active research efforts. Laccase 
can be used in the synthesis of complex medical compounds as anesthetics, anti-
inflammatory, antibiotics, sedatives, etc., including triazolo (benzo) cycloalkyl 
thiadiazines, vinblastine, mitomycin, penicillin X dimer, cephalosporins, and 
dimerized vindoline. 
Poison ivy dermatitis is caused mainly by urushiol, which is a catechol derivative 
toxin. Laccase oxidizes, detoxifies and polymerizes urushiol, [20] which reduces 
the effect of poison ivy dermatitis (oxidized urushiol is non-toxic). Laccase can 
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oxidize iodide to produce iodine which is widely used as a disinfectant. It has 
several advantages over direct iodine application. In terms of handling, storage and 
transport, iodide salt is more stable and much safer as compared to iodine. Release 
of iodine from a laccase iodide system could be easily controlled. The system may 
be used in several medical, industrial, domestic, and other personal care 
applications. A novel application field for laccases is in cosmetics. For example, 
laccase-based hair dyes could be less irritant and easier to handle than current hair 
dyes. Laccase based systems may overcome drawbacks of chemical dyes by 
replacing hydrogen peroxide as the oxidizing agent in the dyeing formula.[21] 
More recently, cosmetic and dermatological preparations containing proteins for 
skin lightening have also been developed. Laccases may find use as deodorants for 
personal-hygiene products, including toothpaste, mouthwash, detergent, soap, and 
diapers. Protein engineered laccase may also be used to reduce allergenicity. 
4.2 Materials and methods 
Poly (lactic-co-glycolic acid) 50:50 (PLGA RESOMER® RG 504H), 38000 -
54000 Dalton, was obtained by Boeringer Ingelheim and used as received. 
Polyvinylpyrrolidone (PVP 856568 Mw 55 KDa) Dimethyl Carbonate (DMC, 
D152927), as solvent of the PLGA, Poly(dimethyl-siloxane) (PDMS), used as 
flexible support, was provided by Sylgard® (184 Silicone Elastomer Kit, Dow 
Corning). Recombinant POXA1b laccase from P. ostreatus expressed in the 
eukaryotic host Pichia pastoris was kindly provided by Biopox srl (Italy). Pig 
cadaver skin was kindly provided by dott.ssa Antonelli Carmela of ASL Napoli 2 
Nord, taken from the butchery implant ICS (Industria Carni Sud) of Caivano, 
Naples (IT). Pig cadaver skin was stained by synthetic blue pigment was kindly 
provided Biopox srl (Italy). 
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4.2.1 Assay of enzymatic activity with ABTS  
Laccase activity was assayed at 25 °C by monitoring the oxidation of ABTS at 
420 nm (ε420 = 36 × 10
3
 M
−1
 cm
−1
). The assay mixture contained 2 * 10
−3
 M ABTS 
in 1 * 10
−1
 M sodium citrate buffer, pH 3.0.  
Enzymatic residual activity of enzyme-charged microneedles was assessed by 
dissolving 10 microneedles in 0.1 ml of DMC and, after a complete dissolution, the 
related solution was rapidly buffered in 50 µl of PBS buffer. Enzymatic activity of 
enzyme-charged microparticles was assessed by dissolving 5 mg of microparticles 
in 0.2 ml of DCM, and after a complete dissolution, the related solution was rapidly 
buffered in 895 µl of PBS buffer. The related enzymatic activity was compared 
with the one detected into the formulation solution by carrying out the same 
dilutions. Enzymatic activity of laccase was determined using ABTS as a substrate 
[22] by measuring UV absorbance at 420 nm. Maximum linear rate ΔA405nm/minute 
was used to calculate the activity (Enzymatic assay of peroxidase from horseradish, 
EC 1.11.1.7, Sigma Prod. No. P-6782). 
4.2.2 Microspheres production  
For the preparation of the solution consisting of the discontinuous phase, 100 mg of 
polymer (83 mg of PLGA and 17 mg of Pluronic F68) were dissolved in 1 ml of 
solvent dichloromethane (DCM), then 70 U of laccase were added to the solution. 
The emulsification process was performed with the Ultra-turrax that is a 
homogenizer. The first emulsion has been prepared for 30 s at 15000 rpm and 
added to the continuous aqueous phase based on 10 ml of PVA solution (at 2% 
w/v). Second emulsion has been carried out always with the same instrument for 1 
min at 20000 rpm. After that, the solution is kept under mechanical stirring for 
about 2 h and 30 min, at a speed of 450 rpm, to remove completely the polymeric 
solvent trough evaporation method. The whole process was carried out by 
refrigerating in ice, in order to avoid the enzyme denaturation. The microparticles 
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are rinsed with deionized water to remove the PVA from the solution with 3 
centrifuges of 10 min at 15000 rpm. For their conservation, they are filtered from 
the water, frozen at – 80°C for 15 min and then subjected to freeze-drying over-
night.  Finally, the as produced microparticles were stocked at 4°C.   
4.2.3 Polymeric microneedles 
New method for to produce biocompatible multi-compartment microneedles for 
cosmeceutical application was discussed, it is possible divided the process in four 
steps:  
1. production of microneedles tips with hydrophilic polymer through 
degassing and spinning; 
2. microparticles inserted in the stamp; 
3. PLGA microparticle sintered with a room temperature process, with a 
mixture of solvent not solvent; 
4. deposition of hydrophilic polymer on the medical tape. 
4.2.4 Production process 
The solvent mixture was composed by 4 ml of ethanol and 0.5 ml of DMC. The 
temperature and the pressure were set respectively at 25.3°C and 0.15 bar. The tip 
of microneedles is produced with a hydrophilic polymer inserted in the cavities of 
the mold through degasing and then spinning. In the second step microparticles 
were inserted in the cavities of the mold in order to produce the base of 
microneedles, and then the mold was placed under the tube in which the 
plasticizing vapor flows. After 2 min it can be observed the plasticization of the 
microspheres that assume the shape of microneedles. Finally, in order to extract the 
microneedles from the stamp a 3M medical tape with a hydrophobic layer was 
used.  
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4.2.5 Characterization of microneedles 
The microneedles were characterized with several analyses to study morphological 
aspect, distribution of drug and mechanical resistance. 
4.2.5.1 Porosity 
In order to check the final microstructures of the microneedles, they were sectioned 
as described above at a thickness of 5 μm. A morphological analysis was 
performed using scanning electron microscope (SEM) (field emission Ultra plus 
Zeiss). Microneedles microstructure was compared to the one of the basic 
microparticles to assess no significant variations consequent to the plasticizing 
process. Samples were sputter coated with a 15 nm thick gold layer and to avoid 
damage inside them, it was imposed a voltage (EHT) of maximum 10 kV.  
4.3 Results and Discussion 
The encapsulation of catalyzers in biodegradable polymer microneedles may 
represent a simple method to deliver enzymes in human skin for dermatology and 
cosmetics treatments.[23, 24] The cosmetics sector is interested in enzymes that 
enhance the beauty of the skin or defend itself against the ravages of the 
environment. One of the most interesting application of enzymes in this field is 
based on free radical scavengers that help to protect the skin by neutralizing 
dangerous substances generated by sun exposure and pollution.[25] Superoxide 
dismutase and peroxidase have been frequently used for their ability to reduce UV-
induced erythema by working synergistically and they may help to slow the visible 
signs of aging and the damaging effects of the environment on the epidermis. The 
action of endogenous enzymatic system of human cells neutralizes the superoxide 
anions and can produce hydrogen peroxide having a detrimental effect on the lipid 
barriers of the skin. Peroxidase can work to neutralize hydrogen peroxide thus 
giving a full spectrum of free radical protection. However, since creams are not 
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effective in the delivery of high molecular weight molecules such as enzymes, 
invasive injection systems are typically used. In this scenario, painless 
biodegradable polymer microneedles represent a promising tool. In the present 
work we loaded polymeric and multi-compartmental microneedles with laccase as 
model enzyme. 
The formation of a solid-state formulation in a microfabrication process involves 
recurring dipping-drying cycles, which can be potentially detrimental to sensitive 
biologically active agents.  
The method used in this work to produce polymeric microneedles overcomes this 
limit. A new stamp based method has been used for the production of 
microneedles. The multi-compartmental feature of the proposed microneedles is 
obtained with a tip of hydrophilic matrix embedding enzyme and porous 
microspheres embedding enzyme everything processed at room temperature to 
preserve the enzyme activity. In particular, microparticles have been placed inside 
the cavities of the mold and then plasticized at room temperature by means of a 
suitable mixture of a solvent, DMC and a non-solvent, EtOH, with respect to 
PLGA to assemble microparticles in the shape of microneedles from one side and 
to keep their microstructures from the other side according to the patented 
procedure.[26] Such microneedles have then been harvested from the mold by 
means of a water-soluble polymeric layer, and indentation test in vitro have been 
carried out to demonstrate the mechanical properties of microneedles and the 
conservation of enzyme activity after the process of microneedles production.   
4.3.1 Microspheres production 
Polymeric microspheres have been employed as starting material for the production 
of biodegradable polymeric microneedles. Such microspheres have been produced 
by means of a double emulsion process to obtain micropores for the encapsulation 
of the enzyme. The double emulsion process allows to encapsulate hydrophilic and 
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hydrophobic molecular. The microspheres were made of PLGA and enzyme 
laccase. PLGA was selected since it is a very well- known biodegradable material, 
which is FDA approved, and has suitable mechanical properties for the production 
of microneedles for drug delivery,[27] In particular, a T25 digital ULTRA-
TURRAX was used for the double emulsion which allowed to produce porous 
microspheres in the range of 1-15 µm. 
 
Fig. 4.3. SEM image of Porous Microspheres 
 
 
 
 
 
 
 
 
 
127 
 
4.3.2 Mold production 
The techniques used for the production of microneedles is a stamp based method 
where the stamp is made of PDMS cavities of conical shape 300 µm of height and 
150 µm of base diameter fig 4.4.   
 
Fig. 4.4. Optical microscopy images of: a) section of the PDMS mold (scale bar 1.2 mm), b) view 
from the top of the PDMS mold showing conical shape (scale bar 900 µm). 
4.3.3 Production of microneedles 
As concern the production of the tip of microneedles from a PVP solution at 25% 
containing 70 U of laccase, all the steps of insertion in the stamp, degassing and 
spin coating are schematically reported in the fig. 4.5. 
 
a) 
b) 
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Fig. 4.5 Production process of microneedles tip; a) deposition of PVP with Gilson on the PDMS 
mold; b) degassing process of solution with PUMP; c) spin coating technique to produce only PVP 
microneedles. 
 
Then the PLGA microspheres containing the enzyme with a diameter in the range 
of 1-15 µm and previously described were placed inside the cavities of the mold 
under a stereomicroscope as schematically depicted in the fig. 4.6.  
 
Fig. 4.6. Microspheres in the cavities of the mold (scale bar 300 µm). 
 
After filling up the mold with the microspheres, it was placed under the tube in 
which the plasticizing vapour flows. This tube was connected to a jacketed 
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Dreschel Bottle, in which there is a mixture of solvent-non solvent. This set up has 
been developed ad hoc for this process and is reported in fig.2.7. 
 
 
Fig. 4.7. System used for the plasticization of the microspheres. 
 
The solvent mixture started to evaporate at room temperature 25.3°C, with a 
nitrogen pressure of 0.1 bar, and the plasticization of the microsphere started. After 
a time ranging from 2 min of this procedure the microspheres assembled assuming 
the shape of the mold cavities. In this process, to the extract the microneedles by 
the stamp a 3M Medical Tape was used after a deposition of a droplet of 
hydrophilic matrix.  
 
Fig. 4.8. a) deposition of hydrophilic polymeric matrix on medical tape; b) 3M medical tape. 
 
a)  b)  
130 
 
The process here described is used to obtain multi-compartmental microneedles, as 
it is possible to observe from the optical image reported in the fig.4.8. Indeed, it is 
possible to observe the tip of microneedles obtained with only hydrophilic matrix, 
and the truncated cone in the base obtained with soft sintering of PLGA 
microparticles. 
 
Fig. 4.8. Stereomicroscope image of microneedles array (scale bar 600 µm) 
4.3.4 Porosity analysis 
The morphological analysis of microneedles was performed with a Scanning 
Electron Microscope (SEM), to understand if the process used for the production of 
microneedles could alter the morphology of the microspheres. For this reason, 
microneedles and microspheres were incorporated in PDMS, cured for 48 h at 
room temperature, and then frozen at -130 °C in Leica Cryo Ultra Microtome EM-
FC7-UC7. Samples were sectioned at a thickness of 5 µm for analysis in axial 
direction.  
Microneedles porosity is of fundamental importance since it determines the drug 
release kinetics. Additionally, a possible loss of homogeneous distribution of the 
porosity may also affect mechanical properties of the final microneedles, 
compromising its indentation ability. Samples were sputter coated with a 15 nm 
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thick gold layer and to avoid damage inside them, it was imposed a voltage (EHT) 
10-20 kV.  
Morphological analysis of porosity was carried out both on microneedles and on 
microspheres sections fig. 4.9. The figure show that the microstructure is very 
similar. Our method allows to preserve both the microstructure and molecule 
distribution of the starting microspheres, providing shaped microparticles that can 
release enzyme over time. In particular, we demonstrate that the shaped 
microparticles keep a porous microstructure and enzyme distribution similar to that 
of the starting microspheres, whereby the release of enzyme embedded in the 
shaped microparticles and starting microspheres is equivalent.  
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Fig. 4.9. a) SEM images of  microparticles slice b) SEM image of micronedlees slice c) SEM image 
of microparticles performing microneedles  
a) 
c) 
b) 
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4.3.5 Efficiency Analysis 
Microparticels were sectioned in slices to monitor the presence an the preservation 
of laccase encapsulated in their porous. In more detailes, a solution of ABTS and 
buffer was add on the slices in order to control the enzyme activites. In case of 
active enzymes, this contact produces an oxidation of the enzyme encapsulated in 
the porous of microparticles. In fact, from the fig. 4.10, the differnce between the 
slice without solution of ABTS in Buffer in the left an with solution in right. The 
presence and the activity of enzyme was confirmed to the green color in the pores 
of microparticles.  
   
 
Fig. 4.10. a) microscope image of micoparticles slice; b) microscope image of microparticles slice 
with solution of ABTS and buffer. (Scale bar 10 µm) 
 
By measuring the quantity of laccase encapsulated after the microparticles 
preparation and by comparing with the quantity of this enzyme used during the 
microparticles production, we obtained that the percentage ratio of encapsulated 
laccase, namely efficiency, was about 80 %. The amount of encapsulated laccase 
did not change in the day subsequent to the microparticle production as reported in 
fig. 4.11. 
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Fig 4.11 Amount of laccase encapsulation of microparticles after different days since the 
production. Blue column represents the initial enzyme used for the preparation of microparticles.  
 
4.3.6 Skin decolorization  
Indentation tests have been conducted to understand the mechanical properties of 
microneedles product with this now stamp based method, but at same time it is 
used for to understand if the encapsulated enzyme was still active after 
microneedles fabrication. 
For this experiment the pig cadaver skin was stained by synthetic blue pigment 
kindly provided Biopox srl (Italy) and by using the applicator system of SMICNA 
for the application of the microneedles. 
Two experiments were carried out in parallel, in fact two pieces of skin were 
stained with same pigment, and for the indentation two different arrays of 
microneedles were test fig. 4.12. The microneedles were prepared with same 
process, but one was loaded with the enzyme while the other one was without 
enzyme. 
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In parallel, control samples were maintained with heat inactivated partially purified 
laccase. After one day it was possible to see by the figure that there is a 
decoloration of the skin where was used the microneedles loaded with enzyme. 
 
 
 
 
Fig. 4.12 Left) skin tested with microneedles without enzyme, and right) skin tested with 
microneedles embedding enzyme.  
These preliminary results indicate that the conditions of the microneedles 
fabrication are mild enough to preserve laccase enzyme activity and that released 
enzyme from microneedles dissolution is functionally active. 
4.4 Conclusions  
Microneedles and in particular polymeric microneedles in the last years are 
considered as a great alternative to the traditional system for drug delivery.  
They permit the encapsulation of high molecular weight, hydrophilic and 
hydrophobic molecules, since the microneedles pass through stratum corneum. In 
particular, this work was focused on the study of a new fabrication stamp based 
method of an array of microneedles for the encapsulation of an enzyme for skin 
lightening in the field of cosmeceutical applications. The results confirmed that the 
process do not produce a denaturation of the encapsulated enzyme.  
Then, thanks to the multi-compartment approach for the realization of 
microneedles it is possible to promote a prolonged release combined to a fast 
release.  
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